How many companies are developing Head and Neck Cancer treatments?

11 companies have active or registered Head and Neck Cancer programs in TheraRadar's competitive landscape (91 classified trials). The most active are Sichuan Baili, GSK, and Johnson & Johnson.

What mechanisms of action are being developed for Head and Neck Cancer?

14 distinct mechanisms of action appear across the Head and Neck Cancer pipeline, including EGFR / HER3 bispecific ADC, EGFR × HER3 bispecific, PD-1 (dostarlimab), EGFR × HER3 bispecific ADC, and EGFR / MET bispecific.

What is the most crowded mechanism in Head and Neck Cancer?

EGFR / HER3 bispecific ADC is the most contested mechanism in Head and Neck Cancer, with 6 programs mapped to it.

Are there upcoming Head and Neck Cancer clinical readouts or FDA decisions?

Near-term Head and Neck Cancer catalysts include SYS6010 injection (data readout, Jun '26); Pembrolizumab (FDA decision, Aug '26); BL-B01D1 (data readout, Nov '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.

Where does TheraRadar's Head and Neck Cancer landscape data come from?

Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.

Landscape / Oncology

Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Head and Neck Cancer Clinical Trial Landscape

Head and neck cancer is a group of cancers that start in the squamous cells lining the moist surfaces of the head and neck, such as the mouth, throat, and voice box. Clinical trials are essential for advancing treatment options and improving outcomes for patients affected by these cancers.

Since 2008, 1,196 trials have been registered, with 520 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 1 and Phase 2, with 224 and 333 trials respectively, while Phase 3 trials account for 55 active studies.

This suggests a strong focus on early-stage drug development and investigation of novel therapeutic approaches. Sichuan Baili Pharmaceutical Co., Ltd. leads industry sponsorship with 8 active trials, followed by AstraZeneca with 6.

V. are also prominent sponsors, each with 4 active trials.

The relatively small number of Phase 4 trials (6 active) suggests limited activity in confirmatory studies and long-term outcome research.

Trial activity

533 active / 1,232 total since 2008

Active by phase 56 Ph3 / 112 335 Ph2 / 722 133 Ph1 / 372 9 Ph4 / 26

Competitive Intelligence

This Head and Neck Cancer competitive landscape maps 11 companies against 14 mechanisms of action (MOA) across 15 active drug-development programs, including 1 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Head and Neck Cancer, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 11 companies 14 mechanisms 15 programs mapped 5 lowTrust (33%) 1 ⚖ PDUFA-dated ⏰ 4 due ≤6 mo click any cell → asset tearsheet

At a glance

Head and Neck Cancer shows 15 programs across 11 companies and 14 mechanisms. The most contested mechanism is EGFR / HER3 bispecific ADC (6 programs).

Key findings

83% of EGFR / HER3 bispecific ADC programs (5 of 6) are combos with novel agents — class-extension work, not class-validation.
Top 3 mechanisms (EGFR / HER3 bispecific ADC, EGFR × HER3 bispecific, EGFR) account for ~16% of programs — class concentration is low.
Sichuan Baili runs 13 programs — the deepest pipeline in this view.
25 hot readouts in next 6 months — most imminent: Sichuan Baili (EGFR / HER3 bispecific ADC).
27 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
51 single-program mechanisms in the long tail — 14 are Ph2+ first-in-class first-mover bets.
45 NME candidates in the long tail.
Most-novel-of-novel: Johnson & Johnson Hafnium-oxide radioenhancer (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 4 due ≤6 mo⚖ 1 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.

⏰ Due soon Hide 🇨🇳 Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →

	EGFR / HER3 bispecific ADC	EGFR × HER3 bispecific	PD-1 (dostarlimab)	EGFR × HER3 bispecific ADC	EGFR / MET bispecific	PD-L1 ADC	PD-1 (Hanzhong)	CD47	EGFR / LGR5 bispecific	PD-1 (cemiplimab)	TCR	EGFR	Nectin-4 ADC	PD-1 (pembrolizumab)
🇨🇳Sichuan Baili
GSK
Johnson & Johnson
🇨🇳Shanghai Henlius
🇨🇳Shanghai Miracogen
ALX Oncology
CSPC Megalith Biopharmaceutic…
Merus B.V.
Rakuten Medical
Corregene
Regeneron

Phase 3 leaders · most advanced

recruiting National Cancer Institute (NCI) NCT06589804
active National Cancer Institute (NCI) NCT05063552
recruiting Canadian Cancer Trials Group NCT06641791
recruiting Oslo University Hospital NCT07580300
recruiting Alliance for Clinical Trials in Oncology NCT06992427

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 13 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.

⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes

Single-program mechanisms (51) — one program each — earliest-stage, sorted by phase

Phase	Mechanism	Company	Modality	Readout	Trial
Ph3	Anti-PD-1 (mAb) 🌱 ⚙️	Akeso		1Q26	NCT04974398
Ph3	Hafnium-oxide radioenhancer ⚡ 🌱 🆕	Johnson & Johnson	IV	2Q28	NCT04892173
Ph3	HGF ⚡ 🌱 🆕	AVEO	IV	3Q27	NCT06064877
Ph2+Ph3	Localized chemotherapy delivery system ⚡ 🌱 ⚙️	Privo Technologies	Oral	⏰ 4Q26	NCT05893888
Ph2+Ph3	OX40 agonist ⚡ 🌱 🆕	Inhibrx	IV	2Q29	NCT06295731
Ph3	PD-1 / CTLA-4 bispecific antibody 🌱 🆕	AstraZeneca		2Q30	NCT06129864
Ph3	PD-1 / VEGF bispecific 🌱 🆕	Akeso	IV	⏰ 1Q27	NCT06601335
Ph3	PROGESTERONE RECEPTOR 🌱	Changchun GeneScience	Oral	2Q27	NCT06772428
Ph3	Topoisomerase II inhibitor ⚡ 🌱 ⚙️	CSPC Zhongnuo Pharmaceuti…	Oral	⏰ 3Q26	NCT05717764
Ph2	Anti-EGFR (mAb) ⚡ 🌱 🆕 ⚙️	Shanghai Henlius		3Q24	NCT05513573
Ph2	Anti-LAG-3 ⚡ 🌱 ⚙️	Incyte Biosciences Intern…	IV	1Q25	NCT05287113
Ph1+Ph2	Anti-PD-L1 (mAb) 🌱 🆕 ⚙️	Shanghai Chia Tai Tianqin…	SC	1Q29	NCT07601204
Ph2	B7-H3 ADC 🌱 🆕	Daiichi Sankyo		3Q28	NCT06330064
Ph2	Botanical anti-inflammatory ⚡ 🌱 🆕 ⚙️	Aveta Biomics		⏰ 4Q26	NCT05312710
Ph2	CDK4/6 🌱	Pfizer	IV	⏰ 4Q26	NCT05226871
Ph1+Ph2	CHK1 inhibitor 🌱 🆕	Sumitomo Pharma America		4Q28	NCT06526819
Ph2	DLL3 ADC 🌱 🆕	Hansoh BioMedical R&D Com…		4Q25	NCT06007729
Ph2	EGFR ADC 🌱 🆕 ⚙️	Shanghai Miracogen	IV	4Q24	NCT05126719
Ph2	HDAC inhibitor ⚡ 🌱 🆕 ⚙️	HitGen		4Q28	NCT06781567
Ph2	HER3 ⚡ 🌱 🆕	Shanghai Institute Of Bio…		⏰ 3Q26	NCT06194656
Ph1+Ph2	HPV 🌱 🆕	Theravectys	IM	⏰ 2Q26	NCT06319963
Ph1+Ph2	HPV E6/E7 ⚡ 🌱 🆕	Cellid		1Q27	NCT06797986
Ph1+Ph2	Hypoxia-activated prodrug 🌱 🆕 ⚙️	AbbVie		4Q27	NCT06782555
Ph2	IL-15 superagonist 🌱 🆕	ImmunityBio	IV	4Q30	NCT07628062
Ph2	LAG-3 🌱 🆕	Regeneron	IV	1Q25	NCT03916627
Ph2	Mitochondrial ROS scavenger ⚡ 🌱 🆕 ⚙️	MitoImmune		4Q25	NCT04651634
Ph1+Ph2	MTAP / PRMT5 🌱 🆕	Amgen	Oral	⏰ 4Q26	NCT05094336
Ph2	Nrf2 activator ⚡ 🌱 🆕 ⚙️	EpicentRx	Oral	3Q27	NCT05966194
Ph2	PD-L1 / VEGF-A bispecific antibody 🌱 🆕	DualityBio		2Q30	NCT06953089
Ph1+Ph2	Personalized neoantigen vaccine 🌱 🆕 ⚙️	Transgene		4Q27	NCT04183166
Ph2	PKC activator ⚡ 🌱 🆕 ⚙️	QBiotics Group Limited		3Q25	NCT05608876
Ph1+Ph2	T CELL RECEPTOR 🌱 🆕	Marengo		⏰ 4Q26	NCT05592626
Ph2	TIGIT 🌱 🆕	Gilead Sciences	IV	⏰ 3Q26	NCT06727565
Ph2	Undisclosed target 🌱 🆕	Sichuan Kelun-Biotech Bio…		3Q28	NCT07668154
Ph1	Anti-SIGNAL (mAb) 🌱 🆕	Boehringer Ingelheim	IV	3Q24	NCT05249426
Ph1	AQP1 ⚡ 🌱 🆕	MeiraGTx	Gene therapy	⏰ 3Q26	NCT02446249
Ph1	Boron neutron capture agent ⚡ 🌱 🆕 ⚙️	Neutron	IV	4Q25	NCT07058116
Ph1	c-Met ADC ⚡ 🌱 🆕 ⚙️	AbbVie	IV	2Q29	NCT07241039
Ph1	CD3 × CD28 × PSMA trispecific ⚡ 🌱 🆕 ⚙️	Johnson & Johnson	IV	3Q28	NCT07219212
Ph1	EGFR × c-MET (ADC) 🌱 🆕	Doma Biopharmaceutical（Su…		⏰ 4Q26	NCT06515990
Ph1	HPV16 E6 ONCOPROTEIN ⚡ 🌱 🆕	NexImmune	IV	⏰ 3Q26	NCT05582590
Ph1	HPV16 E6/E7 🌱 🆕	BlueSky Immunotherapies		4Q27	NCT06589609
Ph1	HPV18-specific CAR-T 🌱 🆕 ⚙️	HRYZ	IV	4Q27	NCT05952947
Ph1	IL-12 ⚡ 🌱 🆕	VLP	IV	4Q27	NCT06736379
Ph1	MAGE-A1 (HLA-A*02:01 TCR-T) 🌱 🆕	TScan		⏰ 4Q26	NCT05973487
Ph1	MAGE-A1 × CD3 bispecific 🌱 🆕 ⚙️	Corregene		1Q30	NCT07583316
Ph1	MAPK PATHWAY 🌱 🆕	Erasca	IV	1Q26	NCT04670679
Ph1	Oncolytic adenovirus (TNFα/IL-2 armed) 🌱 🆕	TILT Biotherapeutics	IV	⏰ 4Q26	NCT05222932
Ph1	Radioligand (isotope-labeled) 🌱 🆕	Boehringer Ingelheim		⏰ 3Q26	NCT05068102
Ph1	Superparamagnetic iron oxide (SPIO) ⚡ 🌱 🆕 ⚙️	MegaPro Biomedical		⏰ 2Q26	NCT06540443
Ph1	therapeutic tumor vaccine 🌱 🆕 ⚙️	Therorna		⏰ 3Q26	NCT07081984

Emerging & small-cap sponsors (8) — few programs here — partnering / M&A radar

Phase	Mechanism	Company	Modality	Readout	Trial
Ph2	Nectin-4 ADC	Astellas Pharma Global De…	IV	1Q25	NCT04225117
Ph1	EGFR	EpiBiologics		3Q29	NCT07462377
Ph2	🇨🇳 PD-1 (Hanzhong)	Lepu Biopharma		4Q27	NCT07586124
Ph3	PD-1 (pembrolizumab)	Merck & Co.	IV	3Q24	NCT03765918
Ph3	PD-1 (pembrolizumab)	PDS	IV	1Q29	NCT06790966
Ph3	EGFR	R-Pharm	IV	3Q25	NCT07435324
Ph1+Ph2	TCR	SCG Cell Therapy Pte.	IV	⏰ 4Q26	NCT06505551
Ph2	🇨🇳 EGFR	Shanghai JMT-Bio	IV	4Q25	NCT06892431

Unclassified programs (33) — mechanism not captured yet

Phase	Mechanism	Company	Trial
Ph3	KL-A167, Gemcitabine, Cisplatinunclassified	Sichuan Kelun-Biotech Bio…	NCT05294172
Ph2+Ph3	BNT113, Pembrolizumabunclassified	BioNTech SE	NCT04534205
Ph2+Ph3	Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebounclassified	Bicara Therapeutics	NCT06788990
Ph2+Ph3	Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumabunclassified	Exelixis	NCT06082167
Ph3	YL201, Docetaxel, Capecitabineunclassified	MediLink Therapeutics (Su…	NCT06629597
Ph3	Physician's Choice SOCunclassified	Rakuten Medical, Inc.	NCT03769506
Ph2+Ph3	IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabineunclassified	SUNHO（China）BioPharmaceut…	NCT06719479
Ph3	BupiZenge 25 mg, Lidocaine viscous 2%unclassified	OncoZenge AB	NCT07672236
Ph3	APG-157unclassified	Aveta Biomics, Inc.	NCT07667296
Ph1+Ph2	STX-478, Fulvestrant, Ribociclibunclassified	Eli Lilly and Company	NCT05768139
Ph2	FID007unclassified	Fulgent Pharma LLC.	NCT06332092
Ph2	VS-101, Cisplatinunclassified	VSPharmTech Co.,Ltd.	NCT06959082
Ph1+Ph2	Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combin…unclassified	PT. Prodia Stem Cell Indo…	NCT05261750
Ph2	NRC-2694-A, Paclitaxelunclassified	NATCO Pharma Ltd.	NCT05283226
Ph1+Ph2	YL201, Toripalimab, Cisplatinunclassified	MediLink Therapeutics (Su…	NCT07258979
Ph2	Tislelizumab, BGB-A425, LBL-007unclassified	BeiGene	NCT05909904
Ph1+Ph2	RiMO-301unclassified	Coordination Pharmaceutic…	NCT05838729
Ph1+Ph2	SHR-A2102, Adebrelimab, Cetuximabunclassified	Suzhou Suncadia Biopharma…	NCT07059221
Ph2	VV1, Cemiplimabunclassified	Vyriad, Inc.	NCT04291105
Ph1+Ph2	Ixovex-1, Pembrolizumabunclassified	Psivac Ltd	NCT06549946
Ph1+Ph2	VB10.16, Pembrolizumabunclassified	Nykode Therapeutics ASA	NCT06016920
Ph1+Ph2	TL117, Paclitaxelunclassified	Suzhou Junde Biotechnolog…	NCT04843098
Ph2	LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, …unclassified	Lyvgen Biopharma Holdings…	NCT06378177
Ph1+Ph2	EOS-448, pembrolizumab, inupadenantunclassified	iTeos Belgium SA	NCT05060432
Ph2	IO102-IO103, Pembrolizumab KEYTRUDA®unclassified	IO Biotech	NCT05280314
Ph1+Ph2	EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphami…unclassified	Beijing Biotech	NCT07617805
Ph1+Ph2	axelopran, Pembolizumabunclassified	Glycyx Therapeutics	NCT07662720
Ph1	BI 770371, Pembrolizumab, Cetuximabunclassified	Boehringer Ingelheim	NCT06806852
Ph1	BI 765179, Ezabenlimab, Pembrolizumabunclassified	Boehringer Ingelheim	NCT04958239
Ph1	X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breas…unclassified	Immunolight, LLC	NCT04389281
Ph1	WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK…unclassified	Wugen, Inc.	NCT05674526
Ph1	A Single Arm, Prospective, Open Label, Multi Center, Phase Ib S…unclassified	IntraGel Therapeutics	NCT05200650
Ph1	U87 autologous CAR T-cellunclassified	Shanghai Unicar-Therapy B…	NCT06614686

Drugs in this landscape: Amivantamab · Dostarlimab · Pembrolizumab

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed

Sichuan Baili Pharmaceutical Co., Ltd. 8 0 0

AstraZeneca 6 5 0

Rakuten Medical, Inc. 4 1 2

Merus B.V. 4 0 0

Boehringer Ingelheim 3 1 0

ALX Oncology Inc. 3 0 0

Exelixis 3 0 0

Pfizer 2 2 10

Eli Lilly 2 2 1

Seagen, a wholly owned subsidiary of Pfizer 2 2 1

Regeneron 2 0 2

Inhibrx Biosciences, Inc 2 0 1

ImmunityBio, Inc. 2 0 1

Johnson & Johnson 2 0 0

USWM CT, LLC 2 0 0

All 15 active Head and Neck Cancer sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2024 (112 registered); 2025 saw 101. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (70 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016

2017

2018

2019

2020

2021

2022

2023

101

2024

112

2025

101

2026

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (2)

822

2017 (6)

233

2018 (5)

200

2019 (2)

148

2020 (7)

370

2021 (4)

161

2022 (6)

124

2023 (6)

307

2024 (13)

410

2025 (10)

207

2026 (9)

356

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT06589804 RECRUITING

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI) n=158

NCT05063552 ACTIVE NOT RECRUITING

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI) n=430

NCT06641791 RECRUITING

Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

Canadian Cancer Trials Group n=196

NCT07580300 RECRUITING

Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

Oslo University Hospital n=400

NCT06992427 RECRUITING

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Alliance for Clinical Trials in Oncology n=228

NCT06525220 RECRUITING

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Merus B.V. n=700

NCT07276399 RECRUITING

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Janssen Research & Development, LLC n=500

NCT06295731 ACTIVE NOT RECRUITING

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences, Inc n=410

NCT07528495 RECRUITING

A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's

All India Institute of Medical Sciences n=396

NCT05721755 ACTIVE NOT RECRUITING

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

ECOG-ACRIN Cancer Research Group n=290

NCT05815927 RECRUITING

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

European Organisation for Research and Treatment of Cancer - EORTC n=200

NCT07441681 NOT YET RECRUITING

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NRG Oncology n=454

NCT07535567 NOT YET RECRUITING

Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=386

NCT04966481 RECRUITING

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Washington University School of Medicine n=81

NCT01266044 ACTIVE NOT RECRUITING

Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia

M.D. Anderson Cancer Center n=435

NCT04534205 RECRUITING

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

BioNTech SE n=350

NCT07524452 RECRUITING

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Ming-Yuan Chen n=430

NCT06064877 RECRUITING

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

AVEO Pharmaceuticals, Inc. n=410

NCT06790966 ACTIVE NOT RECRUITING

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PDS Biotechnology Corp. n=252

NCT07509099 NOT YET RECRUITING

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

Ji Dongmei n=316

NCT07467083 RECRUITING

Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy

West China Hospital n=170

NCT06496178 RECRUITING

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Merus B.V. n=600

NCT03519048 ACTIVE NOT RECRUITING

Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma

Gustave Roussy, Cancer Campus, Grand Paris n=197

NCT06788990 RECRUITING

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Bicara Therapeutics n=650

NCT06129864 RECRUITING

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

AstraZeneca n=1,145

NCT04590963 ACTIVE NOT RECRUITING

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

AstraZeneca n=370

NCT07026474 RECRUITING

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Universität des Saarlandes n=214

NCT07435324 ACTIVE NOT RECRUITING

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

R-Pharm n=161

NCT07432087 NOT YET RECRUITING

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Yue He, MD n=246

NCT04967391 ACTIVE NOT RECRUITING

Tumescence in HNC Skin Graft Reconstruction

University of California, Davis n=58

NCT07371897 NOT YET RECRUITING

Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial

Sun Yat-sen University n=154

NCT07320690 NOT YET RECRUITING

De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=356

NCT00956007 ACTIVE NOT RECRUITING

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Radiation Therapy Oncology Group n=702

NCT06851663 RECRUITING

Trop2-targeted immunoPET Imaging of Solid Tumors

RenJi Hospital n=400

NCT06699212 RECRUITING

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Rakuten Medical, Inc. n=412

NCT05273307 ACTIVE NOT RECRUITING

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

University of California, San Francisco n=40

NCT03340896 ACTIVE NOT RECRUITING

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Groupe Oncologie Radiotherapie Tete et Cou n=256

NCT06082167 ACTIVE NOT RECRUITING

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Exelixis n=600

NCT06492460 RECRUITING

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Sun Yat-sen University n=422

NCT05078047 RECRUITING

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

UNICANCER n=646

NCT04178174 RECRUITING

Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

Centre hospitalier de l'Université de Montréal (CHUM) n=360

NCT02998385 ACTIVE NOT RECRUITING

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Groupe Oncologie Radiotherapie Tete et Cou n=342

NCT03576417 ACTIVE NOT RECRUITING

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Groupe Oncologie Radiotherapie Tete et Cou n=680

NCT02999087 ACTIVE NOT RECRUITING

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Groupe Oncologie Radiotherapie Tete et Cou n=707

NCT03769506 ACTIVE NOT RECRUITING

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Rakuten Medical, Inc. n=135

NCT06772428 NOT YET RECRUITING

Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.

Changchun GeneScience Pharmaceutical Co., Ltd. n=96

NCT06719479 NOT YET RECRUITING

A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).

SUNHO（China）BioPharmaceutical CO., Ltd. n=60

NCT06601335 RECRUITING

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Akeso n=510

NCT04747054 RECRUITING

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

UNICANCER n=102

NCT06647563 NOT YET RECRUITING

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=355

NCT06248996 RECRUITING

a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients

Lund University Hospital n=308

NCT03755739 RECRUITING

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University n=200

NCT06102395 RECRUITING

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Beijing Tongren Hospital n=272

NCT05980715 RECRUITING

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=324

NCT05044117 RECRUITING

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Sun Yat-sen University n=220

NCT07667296 NOT YET RECRUITING

APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

Aveta Biomics, Inc. n=826

NCT05050162 SUSPENDED

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology n=1,714

NCT04199104 COMPLETED

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Merck Sharp & Dohme LLC n=511

NCT05523323 COMPLETED

Merck Sharp & Dohme LLC n=112

NCT05386550 TERMINATED

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

EMD Serono Research & Development Institute, Inc. n=166

NCT03258554 COMPLETED

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI) n=196

NCT01302834 COMPLETED

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Radiation Therapy Oncology Group n=987

NCT04157985 COMPLETED

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Dan Zandberg n=161

NCT03358472 COMPLETED

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Incyte Corporation n=89

NCT04338399 COMPLETED

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Adlai Nortye Biopharma Co., Ltd. n=487

NCT04459715 TERMINATED

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

EMD Serono Research & Development Institute, Inc. n=730

NCT02358031 COMPLETED

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Merck Sharp & Dohme LLC n=882

NCT05930938 TERMINATED

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer

Groupe Oncologie Radiotherapie Tete et Cou n=19

NCT01345084 WITHDRAWN

Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab

Eurofarma Laboratorios S.A.

NCT01504815 COMPLETED

Adaptive Radiation Treatment for Head and Neck Cancer

The Netherlands Cancer Institute n=268

NCT03452137 TERMINATED

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Hoffmann-La Roche n=406

NCT01864850 COMPLETED

Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC

Groupe Oncologie Radiotherapie Tete et Cou n=202

NCT02741570 COMPLETED

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Bristol-Myers Squibb n=947

NCT00820248 COMPLETED

Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer

NCIC Clinical Trials Group n=320

NCT01520701 COMPLETED

Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy

Centre Francois Baclesse n=125

NCT05364918 COMPLETED

Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors

Affiliated Cancer Hospital & Institute of Guangzhou Medical University n=100

NCT05802290 COMPLETED

NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN

Gruppo Oncologico del Nord-Ovest n=124

NCT04969861 TERMINATED

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Nektar Therapeutics n=1

NCT02997553 COMPLETED

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

Institut de Cancérologie de Lorraine n=744

NCT02105636 COMPLETED

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Bristol-Myers Squibb n=361

NCT04129320 WITHDRAWN

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

MacroGenics

NCT01950689 COMPLETED

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

The Christie NHS Foundation Trust n=338

NCT02551159 COMPLETED

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

AstraZeneca n=823

NCT02952586 TERMINATED

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Pfizer n=697

NCT03349710 COMPLETED

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Bristol-Myers Squibb n=74

NCT01427478 COMPLETED

Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck

Centre Leon Berard n=134

NCT01126216 TERMINATED

Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

University of Erlangen-Nürnberg Medical School n=221

NCT02369874 COMPLETED

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

AstraZeneca n=736

NCT01969877 COMPLETED

A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.

Lund University Hospital n=298

NCT00608205 COMPLETED

Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer

Case Comprehensive Cancer Center n=69

NCT00609284 COMPLETED

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux

Groupe Oncologie Radiotherapie Tete et Cou n=406

NCT03342352 WITHDRAWN

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Incyte Corporation

NCT00656513 COMPLETED

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Radiation Therapy Oncology Group n=196

NCT02715596 COMPLETED

Changes in Body Composition After EPA Supplementation in Head and Neck Patients

Institut Català d'Oncologia n=54

NCT00615420 COMPLETED

A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer

British Columbia Cancer Agency n=106

NCT00716391 COMPLETED

TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello n=519

NCT03386838 WITHDRAWN

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

NCT03637335 TERMINATED

Comparing Palliative Radiotherapy With or Without Carboplatin

Institut Cancerologie de l'Ouest n=26

NCT00894101 WITHDRAWN

Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

University of California, Irvine

NCT01156142 COMPLETED

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Alliance for Clinical Trials in Oncology n=155

NCT01545687 WITHDRAWN

CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy

Alliance for Clinical Trials in Oncology

NCT01931150 COMPLETED

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center n=11

NCT01161498 TERMINATED

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

BioVex Limited n=5

NCT02303197 COMPLETED

Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis

Tianjin Medical University Cancer Institute and Hospital n=70

NCT01012258 COMPLETED

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Merck KGaA, Darmstadt, Germany n=70

NCT01596933 COMPLETED

Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy

General Hospital Groeninge n=91

NCT01086826 COMPLETED

Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Associazione Volontari Pazienti Oncologici n=320

NCT01177956 COMPLETED

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

Merck KGaA, Darmstadt, Germany n=73

NCT00911326 TERMINATED

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Navidea Biopharmaceuticals n=101

NCT01812486 COMPLETED

Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer

Universitaire Ziekenhuizen KU Leuven n=200

NCT00814359 COMPLETED

Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis

Juravinski Cancer Centre Foundation n=67

NCT00790322 COMPLETED

Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy

Biotec Pharmacon ASA n=130

NCT05136196 RECRUITING

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

NCT07492914 RECRUITING

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

West China Hospital

NCT05172258 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

National Cancer Institute (NCI)

NCT07195734 RECRUITING

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

NCT07172256 RECRUITING

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Yale University

NCT06980038 RECRUITING

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

NCT05420948 RECRUITING

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

University of Chicago

NCT04373642 ACTIVE NOT RECRUITING

"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer

University of Oklahoma

NCT07572864 RECRUITING

Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC

West China Hospital

NCT04152499 ACTIVE NOT RECRUITING

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Klus Pharma Inc.

NCT06997068 RECRUITING

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

NCT07576725 NOT YET RECRUITING

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

NCT07484139 NOT YET RECRUITING

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

UNC Lineberger Comprehensive Cancer Center

NCT06385080 RECRUITING

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Janssen Research & Development, LLC

NCT04414540 ACTIVE NOT RECRUITING

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Trisha Wise-Draper

NCT06660017 NOT YET RECRUITING

Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

University of Oklahoma

NCT04671667 RECRUITING

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT06380816 RECRUITING

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Cancer Research UK

NCT06794372 RECRUITING

[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

John O. Prior

NCT04083599 ACTIVE NOT RECRUITING

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

NCT06769698 RECRUITING

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

NCT06239194 RECRUITING

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

NCT04403620 ACTIVE NOT RECRUITING

HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT07058805 RECRUITING

Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

Olgun Elicin

NCT02734537 RECRUITING

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

ECOG-ACRIN Cancer Research Group

NCT02270814 ACTIVE NOT RECRUITING

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT06532279 RECRUITING

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

NCT07040956 RECRUITING

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

West China Hospital

NCT02641093 ACTIVE NOT RECRUITING

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Trisha Wise-Draper

NCT07524894 NOT YET RECRUITING

Staph Nasal Decolonization to Improve Function and Feeding

David Palma

NCT06305247 ACTIVE NOT RECRUITING

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Ipsen

NCT06710756 RECRUITING

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Perspective Therapeutics

NCT05358548 RECRUITING

ATATcH Alternating Treatment Plans for Advanced Cancer

Rutgers, The State University of New Jersey

NCT07408063 RECRUITING

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

University Health Network, Toronto

NCT01468896 ACTIVE NOT RECRUITING

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT07554768 NOT YET RECRUITING

Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC

Chen Chunyan

NCT06223568 RECRUITING

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

National Cancer Institute (NCI)

NCT07552558 NOT YET RECRUITING

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

NCT07419464 RECRUITING

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Washington University School of Medicine

NCT04114136 RECRUITING

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Dan Zandberg

NCT05108870 ACTIVE NOT RECRUITING

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

University of Chicago

NCT07550972 ENROLLING BY INVITATION

Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

Zhejiang Provincial People's Hospital

NCT05985655 RECRUITING

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

NCT07209189 RECRUITING

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07407582 RECRUITING

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

University of Arizona

NCT07115043 RECRUITING

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AstraZeneca

NCT04080804 ACTIVE NOT RECRUITING

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Dan Zandberg

NCT03389477 ACTIVE NOT RECRUITING

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT06477692 RECRUITING

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

University of Texas Southwestern Medical Center

NCT07361133 NOT YET RECRUITING

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

National Cancer Institute, Egypt

NCT05910827 RECRUITING

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Hummingbird Bioscience

NCT07213934 RECRUITING

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

University of Cincinnati

NCT07529873 NOT YET RECRUITING

Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

Groupe Oncologie Radiotherapie Tete et Cou

NCT05576974 RECRUITING

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

University of Texas Southwestern Medical Center

NCT07423078 RECRUITING

Window of Opportunity in Preserving Laryngeal Function Trial

Matthew Spector

NCT04895709 RECRUITING

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT05913388 RECRUITING

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Providence Health & Services

NCT05075980 ACTIVE NOT RECRUITING

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Mayo Clinic

NCT04938609 ACTIVE NOT RECRUITING

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Providence Health & Services

NCT05952934 RECRUITING

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

University of Arkansas

NCT06161545 RECRUITING

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT06959108 RECRUITING

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Groupe Oncologie Radiotherapie Tete et Cou

NCT06919666 ACTIVE NOT RECRUITING

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

University of Colorado, Denver

NCT03916627 ACTIVE NOT RECRUITING

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Regeneron Pharmaceuticals

NCT06137274 RECRUITING

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT05318027 ACTIVE NOT RECRUITING

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Abramson Cancer Center at Penn Medicine

NCT05980000 ACTIVE NOT RECRUITING

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Washington University School of Medicine

NCT05287113 ACTIVE NOT RECRUITING

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Incyte Biosciences International Sàrl

NCT07465276 RECRUITING

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Dana-Farber Cancer Institute

NCT06535607 RECRUITING

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

AstraZeneca

NCT07491783 NOT YET RECRUITING

Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial

Sichuan Enray Pharmaceutical Sciences Company

NCT07109726 RECRUITING

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

NCT04375384 RECRUITING

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Wake Forest University Health Sciences

NCT06332092 ACTIVE NOT RECRUITING

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Fulgent Pharma LLC.

NCT05269381 RECRUITING

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic

NCT04585750 RECRUITING

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

NCT07035249 RECRUITING

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

West China Hospital

NCT06580054 RECRUITING

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

University of Michigan Rogel Cancer Center

NCT04915183 RECRUITING

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institute on Deafness and Other Communication Disorders (NIDCD)

NCT06627270 RECRUITING

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Case Comprehensive Cancer Center

NCT07065630 RECRUITING

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

University of Chicago

NCT07179315 NOT YET RECRUITING

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

University of Chicago

NCT06747585 RECRUITING

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Alentis Therapeutics AG

NCT07447050 RECRUITING

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

University of California, Irvine

NCT06657222 RECRUITING

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Tubulis GmbH

NCT07447570 RECRUITING

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT06208826 RECRUITING

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

NCT05977907 RECRUITING

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06047379 RECRUITING

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

NCT06727565 ACTIVE NOT RECRUITING

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

Gilead Sciences

NCT05544136 RECRUITING

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT06239220 RECRUITING

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Glenn J. Hanna

NCT03565783 ACTIVE NOT RECRUITING

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

M.D. Anderson Cancer Center

NCT05414032 RECRUITING

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

University Health Network, Toronto

NCT06855212 ACTIVE NOT RECRUITING

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT06096038 RECRUITING

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

UNC Lineberger Comprehensive Cancer Center

NCT07063212 RECRUITING

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT05674396 RECRUITING

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

M.D. Anderson Cancer Center

NCT04868877 ACTIVE NOT RECRUITING

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Merus B.V.

NCT07030257 RECRUITING

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Tasca Therapeutics

NCT07418034 NOT YET RECRUITING

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

University of Maryland, Baltimore

NCT06995508 RECRUITING

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Roswell Park Cancer Institute

NCT06557889 RECRUITING

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Institut Claudius Regaud

NCT06636734 RECRUITING

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Emory University

NCT04862650 ACTIVE NOT RECRUITING

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Marcelo Bonomi

NCT04930432 RECRUITING

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Betta Pharmaceuticals Co., Ltd.

NCT07400094 NOT YET RECRUITING

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

National Medical Research Radiological Centre of the Ministry of Health of Russia

NCT07398664 NOT YET RECRUITING

H101 Plus TACE for r/m HNSCC

West China Hospital

NCT05286060 ACTIVE NOT RECRUITING

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Yonsei University

NCT06052839 RECRUITING

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Dan Zandberg

NCT06289049 RECRUITING

Heavy Strength Training in Head and Neck Cancer Survivors

University of Alberta

NCT05280457 ACTIVE NOT RECRUITING

HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy

Yonsei University

NCT07393477 NOT YET RECRUITING

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

Sir Run Run Shaw Hospital

NCT07278557 RECRUITING

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia

UNC Lineberger Comprehensive Cancer Center

NCT07371234 RECRUITING

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Xiwei XU

NCT07381075 NOT YET RECRUITING

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

West China Hospital

NCT07379424 NOT YET RECRUITING

A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

chen chao Professor

NCT07214987 NOT YET RECRUITING

PDT For Induction Therapy For Head And Neck Cancer

Massachusetts General Hospital

NCT03474497 ACTIVE NOT RECRUITING

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Megan Daly, MD

NCT02919683 ACTIVE NOT RECRUITING

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Dana-Farber Cancer Institute

NCT05366166 ACTIVE NOT RECRUITING

Pembrolizumab Plus Olaparib in LA-HNSCC

UNC Lineberger Comprehensive Cancer Center

NCT07151040 RECRUITING

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

One-carbon Therapeutics AB

NCT02769520 ACTIVE NOT RECRUITING

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Assuntina G. Sacco, MD

NCT06172478 RECRUITING

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

NCT07254585 RECRUITING

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

CSPC Megalith Biopharmaceutical Co.,Ltd.

NCT03468218 ACTIVE NOT RECRUITING

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Emory University

NCT07363031 ENROLLING BY INVITATION

Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy

Instituto Oncoclinicas

NCT05283226 RECRUITING

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

NATCO Pharma Ltd.

NCT07354984 NOT YET RECRUITING

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sun Yat-sen University

NCT06668961 RECRUITING

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.

NCT03546582 ACTIVE NOT RECRUITING

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

RTOG Foundation, Inc.

NCT06194656 RECRUITING

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Shanghai Institute Of Biological Products

NCT05312710 ACTIVE NOT RECRUITING

Safety and Efficacy of APG-157 in Head and Neck Cancer

Aveta Biomics, Inc.

NCT04183166 ACTIVE NOT RECRUITING

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Transgene

NCT03228667 ACTIVE NOT RECRUITING

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

NCT05522985 ACTIVE NOT RECRUITING

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Tianjin Medical University Cancer Institute and Hospital

NCT05317000 RECRUITING

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Barbara Burtness

NCT04141449 ACTIVE NOT RECRUITING

A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation

Brigham and Women's Hospital

NCT07310771 NOT YET RECRUITING

Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II

Fujian Cancer Hospital

NCT04511078 RECRUITING

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

University of Alabama at Birmingham

NCT06725368 RECRUITING

Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Centre Paul Strauss

NCT04198766 ACTIVE NOT RECRUITING

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

NCT04848116 ACTIVE NOT RECRUITING

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01154920 ACTIVE NOT RECRUITING

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT03347838 ACTIVE NOT RECRUITING

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

University of Colorado, Denver

NCT03556228 RECRUITING

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

NCT06943521 RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

NCT07267286 ACTIVE NOT RECRUITING

Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06265285 RECRUITING

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic

NCT05433116 ACTIVE NOT RECRUITING

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Universität des Saarlandes

NCT06107686 RECRUITING

A Study of YL202 in Selected Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

NCT04842162 RECRUITING

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Gustave Roussy, Cancer Campus, Grand Paris

NCT07094685 RECRUITING

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

University of Michigan Rogel Cancer Center

NCT05226871 ACTIVE NOT RECRUITING

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Pfizer

NCT04180371 ACTIVE NOT RECRUITING

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BicycleTx Limited

NCT06088381 RECRUITING

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

University of Maryland, Baltimore

NCT02955290 ACTIVE NOT RECRUITING

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

NCT04074967 ACTIVE NOT RECRUITING

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Dan Zandberg

NCT02923570 ACTIVE NOT RECRUITING

Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT05902988 RECRUITING

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Volastra Therapeutics, Inc.

NCT04643379 ACTIVE NOT RECRUITING

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Washington University School of Medicine

NCT06597565 RECRUITING

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT05706129 RECRUITING

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

ITM Oncologics GmbH

NCT05565417 ACTIVE NOT RECRUITING

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Immunitas Therapeutics

NCT02994069 ACTIVE NOT RECRUITING

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers

Susanne Arnold

NCT04370587 RECRUITING

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

ImmVira Pharma Co. Ltd

NCT05909904 ACTIVE NOT RECRUITING

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

BeiGene

NCT03383094 ACTIVE NOT RECRUITING

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Loren Mell, MD

NCT05044897 ACTIVE NOT RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Sichuan Baili Pharmaceutical Co., Ltd.

NCT05054439 ACTIVE NOT RECRUITING

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Sichuan Baili Pharmaceutical Co., Ltd.

NCT05668858 RECRUITING

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.

NCT06006169 RECRUITING

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT04273061 RECRUITING

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

British Columbia Cancer Agency

NCT05329532 RECRUITING

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Scancell Ltd

NCT07172802 RECRUITING

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

GI Innovation, Inc.

NCT07136545 RECRUITING

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

Taipei Veterans General Hospital, Taiwan

NCT06682793 RECRUITING

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A2 Biotherapeutics Inc.

NCT03631017 ACTIVE NOT RECRUITING

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Memorial Sloan Kettering Cancer Center

NCT03070366 ACTIVE NOT RECRUITING

Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Groupe Oncologie Radiotherapie Tete et Cou

NCT06989671 NOT YET RECRUITING

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

CSPC Megalith Biopharmaceutical Co.,Ltd.

NCT06145412 ACTIVE NOT RECRUITING

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT06856213 RECRUITING

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT05446467 RECRUITING

Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

Zhejiang Provincial People's Hospital

NCT05864144 ACTIVE NOT RECRUITING

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

NCT05608876 ACTIVE NOT RECRUITING

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

QBiotics Group Limited

NCT07105592 RECRUITING

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Fudan University

NCT04675333 ACTIVE NOT RECRUITING

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

ALX Oncology Inc.

NCT04675294 ACTIVE NOT RECRUITING

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

ALX Oncology Inc.

NCT07090317 RECRUITING

Iparomlimab and Tuvonralimab in HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT05586100 ACTIVE NOT RECRUITING

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT07088211 RECRUITING

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT04609280 ACTIVE NOT RECRUITING

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

University of Maryland, Baltimore

NCT07090707 NOT YET RECRUITING

PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT07059221 RECRUITING

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT06935188 RECRUITING

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT06990737 RECRUITING

Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck

University of California, Davis

NCT03247712 ACTIVE NOT RECRUITING

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Providence Health & Services

NCT05086692 RECRUITING

A Beta-only IL-2 ImmunoTherapY Study

Medicenna Therapeutics, Inc.

NCT07055841 RECRUITING

Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Xiuping Ding

NCT04868162 RECRUITING

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Shanghai Miracogen Inc.

NCT05286294 ACTIVE NOT RECRUITING

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders

Oslo University Hospital

NCT05272696 RECRUITING

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Guangdong Provincial People's Hospital

NCT06580002 RECRUITING

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvine

NCT06940180 RECRUITING

Toripalimab With Chemotherapy for Sinus Cancer

Glenn J. Hanna

NCT05726370 RECRUITING

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Dana-Farber Cancer Institute

NCT04305795 ACTIVE NOT RECRUITING

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Rakuten Medical, Inc.

NCT03341936 ACTIVE NOT RECRUITING

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Dana-Farber Cancer Institute

NCT07010120 RECRUITING

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

West China Hospital

NCT06952868 RECRUITING

Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers

China Medical University Hospital

NCT04946968 ACTIVE NOT RECRUITING

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

National Cancer Centre, Singapore

NCT04340258 ACTIVE NOT RECRUITING

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

University of Cincinnati

NCT06494995 RECRUITING

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Fudan University

NCT06943820 RECRUITING

AK129 Combination Therapy for Advanced Solid Tumors

Akeso

NCT06823479 RECRUITING

Towards Cure Via Only Ultra-short ICB in CSCC

The Netherlands Cancer Institute

NCT06978829 RECRUITING

Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

NCT05144698 RECRUITING

RAPA-201 Therapy of Solid Tumors

Rapa Therapeutics LLC

NCT03406247 RECRUITING

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Gustave Roussy, Cancer Campus, Grand Paris

NCT06437522 RECRUITING

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT03726775 ACTIVE NOT RECRUITING

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Groupe Oncologie Radiotherapie Tete et Cou

NCT05527782 ACTIVE NOT RECRUITING

Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Hospital Universitario Doctor Peset

NCT03476681 ACTIVE NOT RECRUITING

Study of NEO-201 in Solid Tumors Expansion Cohorts

Precision Biologics, Inc

NCT06482307 NOT YET RECRUITING

Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

University Medical Center Groningen

NCT06673693 RECRUITING

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Sun Yat-sen University

NCT04651634 ACTIVE NOT RECRUITING

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

MitoImmune Therapeutics

NCT04969315 RECRUITING

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Portage Biotech

NCT06875791 NOT YET RECRUITING

Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.

Fundacion Clinica Valle del Lili

NCT06690216 ENROLLING BY INVITATION

Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

Man Hu

NCT05784688 RECRUITING

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

TiumBio Co., Ltd.

NCT06693323 RECRUITING

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

University of California, Irvine

NCT04291105 RECRUITING

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Vyriad, Inc.

NCT06895369 NOT YET RECRUITING

The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC

Sir Run Run Shaw Hospital

NCT05473156 RECRUITING

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

AP Biosciences Inc.

NCT05835804 NOT YET RECRUITING

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers

Centre Hospitalier Universitaire, Amiens

NCT04802876 ACTIVE NOT RECRUITING

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

SOLTI Breast Cancer Research Group

NCT06781567 RECRUITING

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

HitGen Inc.

NCT06869473 RECRUITING

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Gruppo Oncologico del Nord-Ovest

NCT06876844 RECRUITING

Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT05784012 ACTIVE NOT RECRUITING

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT04191460 RECRUITING

Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer

Erasmus Medical Center

NCT06494943 RECRUITING

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Fudan University

NCT03085719 ACTIVE NOT RECRUITING

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Dana-Farber Cancer Institute

NCT01220583 ACTIVE NOT RECRUITING

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Radiation Therapy Oncology Group

NCT06470217 RECRUITING

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT06814067 NOT YET RECRUITING

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Fudan University

NCT06549946 RECRUITING

Ixovex-1 Single Agent and Combination Therapy

Psivac Ltd

NCT06797986 NOT YET RECRUITING

A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.

Cellid Co., Ltd.

NCT03526835 RECRUITING

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

NCT04857164 RECRUITING

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Yuankai Shi

NCT03708224 RECRUITING

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Alain Algazi

NCT06793761 NOT YET RECRUITING

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

Beijing Tongren Hospital

NCT06782555 RECRUITING

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

NCT06087614 RECRUITING

Dose Escalation Using Hypoxia-adjusted Radiotherapy

Rajiv Gandhi Cancer Institute & Research Center, India

NCT06640725 RECRUITING

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Groupe Oncologie Radiotherapie Tete et Cou

NCT06422403 RECRUITING

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

National University Hospital, Singapore

NCT05877430 RECRUITING

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

CJ Bioscience, Inc.

NCT06016920 RECRUITING

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Nykode Therapeutics ASA

NCT06725498 RECRUITING

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Beijing Tongren Hospital

NCT04843098 ACTIVE NOT RECRUITING

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Suzhou Junde Biotechnology Co., Ltd

NCT06714266 NOT YET RECRUITING

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Shandong Cancer Hospital and Institute

NCT06444009 RECRUITING

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Lei Liu

NCT06699498 NOT YET RECRUITING

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

The First Affiliated Hospital with Nanjing Medical University

NCT05878288 ACTIVE NOT RECRUITING

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Peter MacCallum Cancer Centre, Australia

NCT06648096 RECRUITING

Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

NCT06694350 NOT YET RECRUITING

Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

Zhejiang Provincial People's Hospital

NCT04787042 RECRUITING

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Simcha IL-18, Inc.

NCT03813836 ACTIVE NOT RECRUITING

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

University College, London

NCT04452032 ACTIVE NOT RECRUITING

Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer

Jules Bordet Institute

NCT05156060 RECRUITING

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Natalie Lockney

NCT05286619 RECRUITING

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

University of Malaya

NCT05620134 ACTIVE NOT RECRUITING

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

NCT04913337 ACTIVE NOT RECRUITING

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

NCT06137378 RECRUITING

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

University of Leipzig

NCT06578871 NOT YET RECRUITING

Surgery and Reducing Ionizing Radiation of the Unknown Primary

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT06572514 RECRUITING

De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC

Ruijin Hospital

NCT05229614 RECRUITING

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

CNAO National Center of Oncological Hadrontherapy

NCT06007729 RECRUITING

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Hansoh BioMedical R&D Company

NCT05182866 ACTIVE NOT RECRUITING

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Rakuten Medical, Inc.

NCT06100497 RECRUITING

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Beijing Tongren Hospital

NCT06537011 NOT YET RECRUITING

AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06534762 RECRUITING

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Zhejiang Provincial People's Hospital

NCT06530914 NOT YET RECRUITING

A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma

Lei Liu

NCT06508606 NOT YET RECRUITING

AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC

West China Hospital

NCT06509997 NOT YET RECRUITING

A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma

Lei Liu

NCT06505551 NOT YET RECRUITING

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

SCG Cell Therapy Pte. Ltd.

NCT03283605 ACTIVE NOT RECRUITING

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Centre hospitalier de l'Université de Montréal (CHUM)

NCT06378177 ACTIVE NOT RECRUITING

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Lyvgen Biopharma Holdings Limited

NCT05187338 RECRUITING

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

NCT05060432 ACTIVE NOT RECRUITING

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

iTeos Belgium SA

NCT05955105 RECRUITING

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

NCT06353685 RECRUITING

De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06323369 RECRUITING

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06366945 NOT YET RECRUITING

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06360978 NOT YET RECRUITING

Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer

Assiut University

NCT06345287 RECRUITING

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT05773079 NOT YET RECRUITING

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Nanfang Hospital, Southern Medical University

NCT06265025 RECRUITING

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

GeneMedicine Co., Ltd.

NCT05280314 RECRUITING

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

IO Biotech

NCT06022757 RECRUITING

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Evopoint Biosciences Inc.

NCT06240689 RECRUITING

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT06199271 NOT YET RECRUITING

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Zhongzheng Xiang

NCT06170710 RECRUITING

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT04989725 RECRUITING

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04729543 RECRUITING

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Erasmus Medical Center

NCT06081673 RECRUITING

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT05777824 RECRUITING

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT03865277 NOT YET RECRUITING

Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

Technische Universität Dresden

NCT05980702 RECRUITING

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06016413 NOT YET RECRUITING

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT05993858 NOT YET RECRUITING

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT03997643 RECRUITING

Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT05941338 RECRUITING

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT04807140 RECRUITING

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT05343325 RECRUITING

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Fifth Affiliated Hospital, Sun Yat-Sen University

NCT05595590 RECRUITING

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Tianjin Medical University Cancer Institute and Hospital

NCT04681469 RECRUITING

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Gruppo Oncologico del Nord-Ovest

NCT05025813 RECRUITING

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Queensland Health

NCT04220749 RECRUITING

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT07589049 NOT YET RECRUITING

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study

Sun Yat-sen University

NCT07586124 NOT YET RECRUITING

Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

Lepu Biopharma Co., Ltd.

NCT07601204 NOT YET RECRUITING

Treatment of Recurrent/Metastatic Head and Neck Cancer

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

NCT07602842 NOT YET RECRUITING

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

InduPro, Inc.

NCT07601737 RECRUITING

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NCT07630168 NOT YET RECRUITING

Effects of Infusion Timing on Treatment Response in Solid Tumors

UNC Lineberger Comprehensive Cancer Center

NCT07628062 NOT YET RECRUITING

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

ImmunityBio, Inc.

NCT07623642 NOT YET RECRUITING

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

GV20 Therapeutics

NCT07618624 ENROLLING BY INVITATION

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

Sun Yat-sen University

NCT07617805 RECRUITING

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Beijing Biotech

NCT07631650 NOT YET RECRUITING

Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

Matthew Spector

NCT07632339 RECRUITING

Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT07667400 NOT YET RECRUITING

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT07668154 NOT YET RECRUITING

A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

NCT07662746 RECRUITING

Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT07662720 NOT YET RECRUITING

A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

Glycyx Therapeutics

NCT07662681 RECRUITING

Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT07659678 NOT YET RECRUITING

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT02841748 COMPLETED

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

University of Chicago

NCT04369937 COMPLETED

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Dan Zandberg

NCT02296684 COMPLETED

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT04313504 COMPLETED

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Trisha Wise-Draper

NCT03355560 COMPLETED

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

Trisha Wise-Draper

NCT04665843 COMPLETED

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Hoffmann-La Roche

NCT03650764 COMPLETED

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT05213884 COMPLETED

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Chongqing University Cancer Hospital

NCT03625323 COMPLETED

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Immutep S.A.S.

NCT03574792 COMPLETED

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Roswell Park Cancer Institute

NCT04704453 COMPLETED

Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Institut Claudius Regaud

NCT04799054 TERMINATED

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Ascendis Pharma Oncology Division A/S

NCT05077709 COMPLETED

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

IO Biotech

NCT04847466 COMPLETED

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

National Cancer Institute (NCI)

NCT03370276 COMPLETED

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT05673577 COMPLETED

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

Fudan University

NCT03744468 COMPLETED

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

BeiGene

NCT03386357 TERMINATED

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Erlangen-Nürnberg Medical School

NCT03217188 COMPLETED

Proton Re-Irradiation for Recurrent Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT04883281 COMPLETED

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT01612351 COMPLETED

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

UNC Lineberger Comprehensive Cancer Center

NCT04609566 COMPLETED

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT03313804 COMPLETED

Priming Immunotherapy in Advanced Disease With Radiation

John L. Villano, MD, PhD

NCT02031250 COMPLETED

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

University of Michigan Rogel Cancer Center

NCT03953976 COMPLETED

INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy

University of Texas Southwestern Medical Center

NCT03480672 COMPLETED

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Leipzig

NCT03993353 COMPLETED

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

NCT02499328 COMPLETED

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

AstraZeneca

NCT05551117 TERMINATED

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

MacroGenics

NCT05814666 TERMINATED

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Flamingo Therapeutics NV

NCT03082534 COMPLETED

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

University of California, San Diego

NCT04862455 TERMINATED

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT04139057 COMPLETED

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

Xinqiao Hospital of Chongqing

NCT04169074 TERMINATED

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

University of Arizona

NCT04260802 TERMINATED

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

NCT04326257 COMPLETED

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Dan Zandberg

NCT04997902 COMPLETED

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

NCT05668949 WITHDRAWN

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

M.D. Anderson Cancer Center

NCT05001347 COMPLETED

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

I-Mab Biopharma US Limited

NCT04811027 COMPLETED

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Immutep S.A.S.

NCT04428151 COMPLETED

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Merck Sharp & Dohme LLC

NCT04779151 TERMINATED

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Gustave Roussy, Cancer Campus, Grand Paris

NCT05383170 COMPLETED

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Cytovation AS

NCT01927744 COMPLETED

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

M.D. Anderson Cancer Center

NCT04854499 TERMINATED

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Gilead Sciences

NCT04454489 COMPLETED

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Wake Forest University Health Sciences

NCT06804850 WITHDRAWN

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

West China Hospital

NCT02369458 COMPLETED

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Washington University School of Medicine

NCT05057247 COMPLETED

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Glenn J. Hanna

NCT05169437 TERMINATED

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Tempus AI

NCT04220866 COMPLETED

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Merck Sharp & Dohme LLC

NCT03049618 COMPLETED

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

University of Southern California

NCT06046482 TERMINATED

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT03821272 COMPLETED

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

University of Arkansas

NCT04260126 COMPLETED

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

PDS Biotechnology Corp.

NCT00875849 COMPLETED

Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer

Centre Antoine Lacassagne

NCT05271604 COMPLETED

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BioAtla, Inc.

NCT05061420 TERMINATED

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Sanofi

NCT05459129 COMPLETED

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Hoffmann-La Roche

NCT05323656 COMPLETED

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Calliditas Therapeutics Suisse SA

NCT05259696 COMPLETED

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Palleon Pharmaceuticals, Inc.

NCT05007106 COMPLETED

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Merck Sharp & Dohme LLC

NCT02327078 COMPLETED

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

NCT00665392 COMPLETED

Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT05517330 COMPLETED

Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

West China Hospital

NCT05156970 COMPLETED

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT03729596 TERMINATED

MGC018 With or Without MGA012 in Advanced Solid Tumors

MacroGenics

NCT02892201 TERMINATED

Pembrolizumab in HNSCC With Residual Disease After Radiation

Yale University

NCT03795610 COMPLETED

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Assuntina G. Sacco, MD

NCT05714553 TERMINATED

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

NCT04247282 COMPLETED

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

National Cancer Institute (NCI)

NCT05563272 TERMINATED

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Telix Pharmaceuticals (Innovations) Pty Ltd

NCT05879484 WITHDRAWN

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

National Cancer Institute (NCI)

NCT03440437 TERMINATED

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

invoX Pharma Limited

NCT04282109 COMPLETED

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT03645928 TERMINATED

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

NCT03094169 TERMINATED

AVID100 in Advanced Epithelial Carcinomas

Formation Biologics

NCT04616196 COMPLETED

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Nektar Therapeutics

NCT03317327 COMPLETED

REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors

Oslo University Hospital

NCT05499065 COMPLETED

Real-time Margin Assessment in Head and Neck Cancer

University Medical Center Groningen

NCT06251050 COMPLETED

A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy

West China Hospital

NCT04442126 TERMINATED

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Numab Therapeutics AG

NCT05516589 COMPLETED

Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

West China Hospital

NCT04555837 COMPLETED

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT03944915 COMPLETED

De-Escalation Therapy for Human Papillomavirus Negative Disease

University of Chicago

NCT04633278 TERMINATED

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

NCT04278092 COMPLETED

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Medical University of Vienna

NCT03212469 COMPLETED

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Gustave Roussy, Cancer Campus, Grand Paris

NCT03107182 COMPLETED

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

University of Chicago

NCT00942734 COMPLETED

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT04752384 COMPLETED

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Medical College of Wisconsin

NCT03646461 TERMINATED

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

University of California, San Diego

NCT04383210 TERMINATED

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

NCT03829501 TERMINATED

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab Limited

NCT03754933 COMPLETED

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

GeoVax, Inc.

NCT03602911 COMPLETED

A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

West Virginia University

NCT05743270 WITHDRAWN

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Replimune, Inc.

NCT04032704 TERMINATED

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

NCT02289209 COMPLETED

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Dan Zandberg

NCT03058289 COMPLETED

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Intensity Therapeutics, Inc.

NCT03169764 WITHDRAWN

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

NCT04357873 COMPLETED

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

UNICANCER

NCT06054477 TERMINATED

Study of ALE.C04 in Patients With Head and Neck Cancer

Alentis Therapeutics AG

NCT04666688 COMPLETED

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT03518606 COMPLETED

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

UNICANCER

NCT03504488 COMPLETED

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

BioAtla, Inc.

NCT04815720 COMPLETED

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Vaccinex Inc.

NCT02573493 COMPLETED

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Washington University School of Medicine

NCT05500508 TERMINATED

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Aminex Therapeutics, Inc.

NCT03997968 COMPLETED

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

NCT03946358 COMPLETED

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

Centre Hospitalier Universitaire de Besancon

NCT02538510 COMPLETED

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

NCT03878979 COMPLETED

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04220775 TERMINATED

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT02609503 COMPLETED

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

UNC Lineberger Comprehensive Cancer Center

NCT05265013 TERMINATED

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Rakuten Medical, Inc.

NCT03153982 TERMINATED

Ruxolitinib in Operable Head and Neck Cancer

University of California, San Francisco

NCT00868491 COMPLETED

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

Institute of Oncology Ljubljana

NCT04144517 COMPLETED

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Mural Oncology, Inc

NCT03207867 TERMINATED

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis Pharmaceuticals

NCT03565003 COMPLETED

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Jacobio Pharmaceuticals Co., Ltd.

NCT03521570 COMPLETED

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Emory University

NCT04474470 COMPLETED

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

TyrNovo Ltd.

NCT04721223 COMPLETED

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.

NCT03422536 COMPLETED

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

University of Arizona

NCT05724602 SUSPENDED

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

NCT02777385 COMPLETED

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Dan Zandberg

NCT02776163 COMPLETED

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT06084845 WITHDRAWN

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

ECOG-ACRIN Cancer Research Group

NCT04570839 COMPLETED

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Compugen Ltd

NCT04541355 COMPLETED

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

Hyunseok Kang, MD

NCT03719690 COMPLETED

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Kura Oncology, Inc.

NCT06446570 COMPLETED

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Seoul National University Hospital

NCT03494322 COMPLETED

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

University College, London

NCT04939480 COMPLETED

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

University Hospital, Essen

NCT03723967 COMPLETED

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Centre Leon Berard

NCT03426657 COMPLETED

Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

University of Erlangen-Nürnberg Medical School

NCT04936841 TERMINATED

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

University of Wisconsin, Madison

NCT03665285 COMPLETED

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NextCure, Inc.

NCT05099549 TERMINATED

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NKGen Biotech, Inc.

NCT01979211 COMPLETED

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

University of Cincinnati

NCT04221165 COMPLETED

Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT01330446 COMPLETED

Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer

M.D. Anderson Cancer Center

NCT05918224 COMPLETED

Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy

West China Hospital

NCT01437449 COMPLETED

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Stanford University

NCT03543813 COMPLETED

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

CytomX Therapeutics

NCT03511391 COMPLETED

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

University Hospital, Ghent

NCT05724849 WITHDRAWN

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

NCT03149549 TERMINATED

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

CytomX Therapeutics

NCT04634825 TERMINATED

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

MacroGenics

NCT03894891 COMPLETED

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Dana-Farber Cancer Institute

NCT05363605 TERMINATED

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

NCT03691714 COMPLETED

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Trisha Wise-Draper

NCT06090318 WITHDRAWN

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

NCT01711658 COMPLETED

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Radiation Therapy Oncology Group

NCT03267121 COMPLETED

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT03083873 COMPLETED

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Iovance Biotherapeutics, Inc.

NCT04193293 TERMINATED

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

SecuraBio

NCT05359692 WITHDRAWN

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Incyte Biosciences International Sàrl

NCT04834349 WITHDRAWN

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT05535023 WITHDRAWN

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT02524275 TERMINATED

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

University of Nebraska

NCT02499120 COMPLETED

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Pfizer

NCT05110781 TERMINATED

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

University of California, Davis

NCT03624231 COMPLETED

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Ulrich Keilholz

NCT00707655 TERMINATED

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Genmab

NCT01054625 COMPLETED

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Genmab

NCT00542308 COMPLETED

Zalutumumab in Non-curable Patients With SCCHN

Genmab

NCT03602079 COMPLETED

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

NCT04424641 TERMINATED

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

NCT02207439 COMPLETED

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Abramson Cancer Center at Penn Medicine

NCT03740100 TERMINATED

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

M.D. Anderson Cancer Center

NCT03735680 COMPLETED

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

OncoNano Medicine, Inc.

NCT02949700 COMPLETED

Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

Baylor College of Medicine

NCT01084083 COMPLETED

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Eastern Cooperative Oncology Group

NCT01824823 TERMINATED

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

ECOG-ACRIN Cancer Research Group

NCT02488629 TERMINATED

Study of SCB01A in Patient With Head and Neck Cancer

SynCore Biotechnology Co., Ltd.

NCT03522584 TERMINATED

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

University of Washington

NCT01711541 COMPLETED

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

National Cancer Institute (NCI)

NCT04987996 WITHDRAWN

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Providence Health & Services

NCT02057107 COMPLETED

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Heath Skinner

NCT03769311 COMPLETED

Cetuximab in Head and Neck Cancer Patients

University of Wisconsin, Madison

NCT05743777 WITHDRAWN

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Canadian Cancer Trials Group

NCT02345330 TERMINATED

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

OncoSec Medical Incorporated

NCT03823131 TERMINATED

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Chase Heaton, MD

NCT02823574 COMPLETED

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Bristol-Myers Squibb

NCT03642990 TERMINATED

NR in Chemo-induced Peripheral Neuropathy

Donna Hammond, PhD

NCT03254927 TERMINATED

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Celldex Therapeutics

NCT04208334 COMPLETED

The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer

Phramongkutklao College of Medicine and Hospital

NCT04034225 TERMINATED

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

Sensei Biotherapeutics, Inc.

NCT02291055 TERMINATED

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Advaxis, Inc.

NCT02990468 COMPLETED

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

BioMimetix JV, LLC

NCT02126969 COMPLETED

A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN

Susanne Arnold

NCT03435640 TERMINATED

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Nektar Therapeutics

NCT00702481 COMPLETED

Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer

National Cancer Centre, Singapore

NCT02707588 COMPLETED

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

Groupe Oncologie Radiotherapie Tete et Cou

NCT03356223 COMPLETED

Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6

Centre Leon Berard

NCT01173172 COMPLETED

Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer

Taipei Veterans General Hospital, Taiwan

NCT04685499 TERMINATED

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Weill Medical College of Cornell University

NCT03982537 WITHDRAWN

Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome

Wake Forest University Health Sciences

NCT05219578 TERMINATED

RTX-224 Monotherapy in Patients With Solid Tumors

Rubius Therapeutics

NCT02643303 COMPLETED

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

NCT01874860 COMPLETED

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

University of Louisville

NCT03620123 COMPLETED

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

AIO-Studien-gGmbH

NCT03405142 COMPLETED

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Eben Rosenthal

NCT04242173 TERMINATED

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT02965001 COMPLETED

Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

Rigshospitalet, Denmark

NCT02055963 TERMINATED

Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer

M.D. Anderson Cancer Center

NCT02704169 COMPLETED

Quantitative Endoscopy of H&N

University Health Network, Toronto

NCT01458392 COMPLETED

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

NCT02002182 COMPLETED

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Andrew Sikora

NCT01592721 COMPLETED

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

The University of Texas Health Science Center at San Antonio

NCT03162224 COMPLETED

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

NCT02268695 COMPLETED

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

Groupe Oncologie Radiotherapie Tete et Cou

NCT04529850 COMPLETED

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Galera Therapeutics, Inc.

NCT04831450 WITHDRAWN

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Miami

NCT04849377 WITHDRAWN

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Icahn School of Medicine at Mount Sinai

NCT03057613 COMPLETED

The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

Case Comprehensive Cancer Center

NCT02255097 COMPLETED

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Merck Sharp & Dohme LLC

NCT04880603 TERMINATED

Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site

Nebraska Methodist Health System

NCT03633110 COMPLETED

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Genocea Biosciences, Inc.

NCT05234606 WITHDRAWN

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Silverback Therapeutics

NCT03684785 TERMINATED

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Exicure, Inc.

NCT04428047 TERMINATED

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

UNICANCER

NCT03292250 COMPLETED

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Seoul National University Hospital

NCT03067610 COMPLETED

Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT03330249 COMPLETED

Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion

Groupe Oncologie Radiotherapie Tete et Cou

NCT02684253 COMPLETED

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT01606566 TERMINATED

A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.

PCI Biotech AS

NCT02178722 COMPLETED

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

NCT02318277 COMPLETED

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Incyte Corporation

NCT02901483 TERMINATED

A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

PharmaEngine

NCT03829007 COMPLETED

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Radboud University Medical Center

NCT03937141 TERMINATED

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Chinook Therapeutics, Inc. (formerly Aduro)

NCT01332266 COMPLETED

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Eisai Inc.

NCT02001623 COMPLETED

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

NCT04408898 WITHDRAWN

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Adaptimmune

NCT03245736 COMPLETED

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

NCT03096808 COMPLETED

Adaptive Radiotherapy for Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT02085460 COMPLETED

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

Otsuka Pharmaceutical Co., Ltd.

NCT04052204 TERMINATED

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Pfizer

NCT04607642 WITHDRAWN

Trial of BMX-001 or Placebo in Head and Neck Cancer Patients

BioMimetix JV, LLC

NCT03938337 TERMINATED

Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

University of Alabama at Birmingham

NCT03101514 COMPLETED

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

First Affiliated Hospital of Harbin Medical University

NCT04464967 WITHDRAWN

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

NCT02762513 COMPLETED

Expansion Trial for Axitinib In Head And Neck Cancer

University of Michigan Rogel Cancer Center

NCT03194373 COMPLETED

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

University of Michigan Rogel Cancer Center

NCT01126008 COMPLETED

Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer

Samsung Medical Center

NCT02759575 COMPLETED

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Vinita Takiar

NCT01620242 COMPLETED

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

UNICANCER

NCT01716195 COMPLETED

Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer

University of California, Davis

NCT00904345 TERMINATED

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

University of Michigan Rogel Cancer Center

NCT03887442 TERMINATED

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT01602315 TERMINATED

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Novartis Pharmaceuticals

NCT02423863 COMPLETED

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Oncovir, Inc.

NCT01689194 COMPLETED

Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer

Seoul National University Hospital

NCT03655444 TERMINATED

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Washington University School of Medicine

NCT01412229 COMPLETED

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

UNC Lineberger Comprehensive Cancer Center

NCT04262388 WITHDRAWN

A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

University Health Network, Toronto

NCT03349034 COMPLETED

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

Icahn School of Medicine at Mount Sinai

NCT01386632 COMPLETED

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

Sanford Health

NCT02207530 COMPLETED

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

AstraZeneca

NCT00736944 COMPLETED

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Washington University School of Medicine

NCT04058145 WITHDRAWN

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Massachusetts General Hospital

NCT04093115 WITHDRAWN

Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Beijing Konruns Pharmaceutical Co., Ltd.

NCT04525066 COMPLETED

Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma

Ayhman Al Afif

NCT00833261 COMPLETED

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT00851877 COMPLETED

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT02124707 COMPLETED

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

UNC Lineberger Comprehensive Cancer Center

NCT02842125 TERMINATED

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

MultiVir, Inc.

NCT01133678 TERMINATED

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

University of Chicago

NCT03433027 COMPLETED

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Benitec Biopharma, Inc.

NCT01111058 TERMINATED

Everolimus Versus Placebo in Head and Neck Cancer

University of Chicago

NCT00721513 COMPLETED

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Wake Forest University Health Sciences

NCT00957853 COMPLETED

Preoperative Treatment With Cetuximab and/or IMC-A12

M.D. Anderson Cancer Center

NCT01044433 COMPLETED

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Abramson Cancer Center at Penn Medicine

NCT02452424 TERMINATED

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

NCT01697800 COMPLETED

A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02422979 COMPLETED

Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

Rakuten Medical, Inc.

NCT01744340 COMPLETED

A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer

howard safran

NCT02882308 COMPLETED

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Hellenic Cooperative Oncology Group

NCT03323424 WITHDRAWN

Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers

Institut de Cancérologie de la Loire

NCT03463161 TERMINATED

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

University of Chicago

NCT01998542 COMPLETED

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

Mirror Biologics, Inc.

NCT02335918 COMPLETED

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Celldex Therapeutics

NCT01774760 COMPLETED

Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer

Turku University Hospital

NCT01081041 COMPLETED

A Study in Head and Neck Cancer

Eli Lilly and Company

NCT02454179 COMPLETED

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Acerta Pharma BV

NCT01581970 COMPLETED

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Masonic Cancer Center, University of Minnesota

NCT01016769 COMPLETED

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT02410382 TERMINATED

Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer

University of Arizona

NCT03325465 WITHDRAWN

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

University of Chicago

NCT01264328 COMPLETED

Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT02706691 TERMINATED

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

University of Chicago

NCT00765011 COMPLETED

TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

NCT02946021 COMPLETED

Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema

Tactile Medical

NCT03114280 WITHDRAWN

Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)

Centre Antoine Lacassagne

NCT00750555 TERMINATED

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Geisinger Clinic

NCT02976883 COMPLETED

[18F]HX4 PET/CT Imaging for Detection of Hypoxia

Nottingham University Hospitals NHS Trust

NCT00573989 TERMINATED

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Wake Forest University Health Sciences

NCT01696955 COMPLETED

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT03246685 TERMINATED

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

HiberCell, Inc.

NCT00756444 COMPLETED

A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

Amgen

NCT00896454 COMPLETED

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Amgen

NCT01653327 COMPLETED

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

Dartmouth-Hitchcock Medical Center

NCT01218048 COMPLETED

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Robert Ferris

NCT01732640 TERMINATED

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01852292 TERMINATED

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Novartis Pharmaceuticals

NCT02540928 TERMINATED

AMG 319 in HPV Positive and Negative HNSCC

Cancer Research UK

NCT01009346 TERMINATED

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00646659 TERMINATED

Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

European Organisation for Research and Treatment of Cancer - EORTC

NCT01252628 COMPLETED

Phase 1 and 2 Study of PX-866 and Cetuximab

Cascadian Therapeutics Inc.

NCT01204099 COMPLETED

Study of PX-866 and Docetaxel in Solid Tumors

Cascadian Therapeutics Inc.

NCT00617734 COMPLETED

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Eli Lilly and Company

NCT01984892 TERMINATED

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Nina Bhardwaj

NCT01488318 TERMINATED

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Julie E. Bauman, MD, MPH

NCT03238638 WITHDRAWN

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

University of Chicago

NCT01051791 TERMINATED

Phase II Study of RAD001 Head and Neck Cancer

Julie E. Bauman, MD, MPH

NCT01221753 TERMINATED

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Dana-Farber Cancer Institute

NCT01237483 COMPLETED

Reirradiation and Erbitux in the HNSCC

Groupe Oncologie Radiotherapie Tete et Cou

NCT02135185 COMPLETED

Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent

Institut du Cancer de Montpellier - Val d'Aurelle

NCT01733823 COMPLETED

DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

Danish Head and Neck Cancer Group

NCT00704639 COMPLETED

Chemoradiation Treatment for Head and Neck Cancer

Trans Tasman Radiation Oncology Group

NCT01807546 COMPLETED

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

NCT01528163 COMPLETED

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT01794845 TERMINATED

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

University of Miami

NCT01467115 COMPLETED

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Drexel University College of Medicine

NCT00927147 TERMINATED

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Boneca Corporation

NCT01040832 COMPLETED

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

EMD Serono

NCT02281006 TERMINATED

Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity

CHU de Quebec-Universite Laval

NCT01577173 COMPLETED

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Genentech, Inc.

NCT01469546 COMPLETED

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

University of Michigan Rogel Cancer Center

NCT01405846 TERMINATED

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

Papworth Hospital NHS Foundation Trust

NCT01045421 COMPLETED

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Millennium Pharmaceuticals, Inc.

NCT00968435 COMPLETED

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT01820312 WITHDRAWN

A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)

University of Arkansas

NCT02143622 WITHDRAWN

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Novartis Pharmaceuticals

NCT00872404 TERMINATED

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT02479178 TERMINATED

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

BIND Therapeutics

NCT01285635 TERMINATED

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

University of Michigan Rogel Cancer Center

NCT02047201 COMPLETED

Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC

Lithuanian University of Health Sciences

NCT02430298 COMPLETED

Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients

Khon Kaen University

NCT01695122 COMPLETED

Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

Instituto do Cancer do Estado de São Paulo

NCT01333085 COMPLETED

Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery

GERCOR - Multidisciplinary Oncology Cooperative Group

NCT01183065 COMPLETED

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT00720083 TERMINATED

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Radiation Therapy Oncology Group

NCT02061631 COMPLETED

Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

Sanofi

NCT01312493 WITHDRAWN

Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

UNC Lineberger Comprehensive Cancer Center

NCT01701466 TERMINATED

Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis

Sir Mortimer B. Davis - Jewish General Hospital

NCT00827164 COMPLETED

Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer

University of Alabama at Birmingham

NCT00713219 COMPLETED

Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT00881114 WITHDRAWN

Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer

Georgetown University

NCT01548846 TERMINATED

Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract

Centre Francois Baclesse

NCT01219673 TERMINATED

Symptom Burden in Head and Neck Cancer

M.D. Anderson Cancer Center

NCT01164176 COMPLETED

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Yonsei University

NCT01465308 COMPLETED

The Effect of Honey on Xerostomia and Oral Mucositis

Cyprus University of Technology

NCT01903018 COMPLETED

A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00

Piramal Enterprises Limited

NCT01305772 TERMINATED

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

Neal Ready

NCT00918281 COMPLETED

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

GE Healthcare

NCT01425736 COMPLETED

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

Wei Guo

NCT00971932 COMPLETED

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Merck KGaA, Darmstadt, Germany

NCT00959387 COMPLETED

Induction Chemotherapy for Advanced Head and Neck Cancer

Barretos Cancer Hospital

NCT00791141 COMPLETED

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer

Heinrich-Heine University, Duesseldorf

NCT01172769 COMPLETED

Efficacy Study of Temsirolimus to Treat Head and Neck Cancer

Hannover Medical School

NCT01075399 COMPLETED

Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors

Siemens Molecular Imaging

NCT00824343 COMPLETED

A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer

Piramal Enterprises Limited

NCT00908024 TERMINATED

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

NCT01245985 TERMINATED

TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors

Heidelberg University

NCT01427205 WITHDRAWN

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

M.D. Anderson Cancer Center

NCT01506427 WITHDRAWN

A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

Siemens Molecular Imaging

NCT01015664 TERMINATED

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

University of Tennessee Cancer Institute

NCT01415986 TERMINATED

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

University of Arkansas

NCT00899054 COMPLETED

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

Piramal Enterprises Limited

NCT01280318 COMPLETED

Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT00714649 COMPLETED

Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT01213030 COMPLETED

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

NCT00737360 TERMINATED

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Taiho Pharmaceutical Co., Ltd.

NCT01645748 COMPLETED

Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer

Chonnam National University Hospital

NCT00910117 COMPLETED

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Fudan University

NCT01313390 TERMINATED

Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

University College, London

NCT00805012 TERMINATED

Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Seoul National University Hospital

NCT00756951 COMPLETED

Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

SciClone Pharmaceuticals

NCT05294900 COMPLETED

Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients

Yonsei University

NCT03789097 COMPLETED

Vaccination With Flt3L, Radiation, and Poly-ICLC

Icahn School of Medicine at Mount Sinai

NCT01451853 WITHDRAWN

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

NCT05721443 COMPLETED

Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT05708950 COMPLETED

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

NCT05005403 RECRUITING

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

NCT07583316 NOT YET RECRUITING

A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors

Corregene Biotechnology Co., Ltd

NCT07583914 NOT YET RECRUITING

Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors

West China Hospital

NCT05172245 RECRUITING

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

NCT06673329 RECRUITING

Brodalumab in the Treatment of Immune-Related Adverse Events

Brian Henick, MD

NCT07156227 RECRUITING

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT05877599 RECRUITING

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AstraZeneca

NCT07584499 RECRUITING

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

Sun Yat-sen University

NCT06465069 RECRUITING

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Eli Lilly and Company

NCT06806852 ACTIVE NOT RECRUITING

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Boehringer Ingelheim

NCT05249426 ACTIVE NOT RECRUITING

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Boehringer Ingelheim

NCT05068102 ACTIVE NOT RECRUITING

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Boehringer Ingelheim

NCT07085091 RECRUITING

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Oncology Inc.

NCT05581004 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

NCT07217028 RECRUITING

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Vanderbilt-Ingram Cancer Center

NCT07567235 RECRUITING

Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis

West China Hospital

NCT04389632 RECRUITING

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT05747625 RECRUITING

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Eben Rosenthal

NCT07219212 RECRUITING

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Johnson & Johnson Enterprise Innovation Inc.

NCT07462377 RECRUITING

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

EpiBiologics

NCT03132922 ACTIVE NOT RECRUITING

MAGE-A4ᶜ¹º³²T for Multi-Tumor

USWM CT, LLC

NCT07279116 NOT YET RECRUITING

ABY-029 Head & Neck Trial

Dartmouth-Hitchcock Medical Center

NCT07101432 RECRUITING

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

M.D. Anderson Cancer Center

NCT07040072 RECRUITING

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Beijing Tongren Hospital

NCT02495896 ACTIVE NOT RECRUITING

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

University of Southern California

NCT03803774 ACTIVE NOT RECRUITING

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT07545967 RECRUITING

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

West China Hospital

NCT06147037 RECRUITING

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

AstraZeneca

NCT02812524 ACTIVE NOT RECRUITING

Ipilimumab for Head and Neck Cancer Patients

Providence Health & Services

NCT07020117 RECRUITING

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

NCT05208762 RECRUITING

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT06150664 RECRUITING

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Compass Therapeutics

NCT05039801 RECRUITING

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

NCT07455032 RECRUITING

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Fox Chase Cancer Center

NCT04533750 ACTIVE NOT RECRUITING

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

NCT06238479 ACTIVE NOT RECRUITING

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Eli Lilly and Company

NCT05858736 ACTIVE NOT RECRUITING

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

OncoC4, Inc.

NCT07517198 RECRUITING

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

NCT06444815 RECRUITING

A Study of VET3-TGI in Patients With Solid Tumors

KaliVir Immunotherapeutics

NCT07216105 RECRUITING

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

NCT07090499 RECRUITING

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Pfizer

NCT04044859 ACTIVE NOT RECRUITING

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

USWM CT, LLC

NCT06451497 RECRUITING

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

NCT06236425 ACTIVE NOT RECRUITING

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT05891171 ACTIVE NOT RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Arcus Biosciences, Inc.

NCT07503808 RECRUITING

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

IDEAYA Biosciences

NCT07501650 RECRUITING

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Thomas Jefferson University

NCT04722523 RECRUITING

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT07457281 RECRUITING

GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

West China Hospital

NCT05635643 RECRUITING

Study of CHS-114 in Participants With Advanced Solid Tumors

Coherus Oncology, Inc.

NCT04007744 ACTIVE NOT RECRUITING

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Mayo Clinic

NCT04119024 RECRUITING

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Anusha Kalbasi

NCT05176483 RECRUITING

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT06211335 RECRUITING

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

University of California, Davis

NCT07460765 NOT YET RECRUITING

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Vanderbilt-Ingram Cancer Center

NCT07227168 RECRUITING

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Sutro Biopharma, Inc.

NCT05901545 RECRUITING

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

NCT06868433 RECRUITING

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

NCT05526924 RECRUITING

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

University of Chicago

NCT07272642 NOT YET RECRUITING

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Radiopharm Theranostics, Ltd

NCT06778863 RECRUITING

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Clasp Therapeutics, Inc.

NCT07182149 RECRUITING

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity AccelCo, Inc.

NCT05820711 ACTIVE NOT RECRUITING

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

University of Wisconsin, Madison

NCT05239143 ACTIVE NOT RECRUITING

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Poseida Therapeutics, Inc.

NCT03740256 RECRUITING

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Baylor College of Medicine

NCT06242470 RECRUITING

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

NCT04754321 RECRUITING

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Ohio State University Comprehensive Cancer Center

NCT05983432 RECRUITING

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

SystImmune Inc.

NCT02432963 ACTIVE NOT RECRUITING

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

City of Hope Medical Center

NCT06997094 RECRUITING

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Mayo Clinic

NCT07348211 RECRUITING

First in Human Study of SIM0610 in Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

NCT07358806 RECRUITING

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Oscotec Inc.

NCT07358884 NOT YET RECRUITING

First in Human Study of QLS5316 in Solid Tumors

Qilu Pharmaceutical Co., Ltd.

NCT06736379 RECRUITING

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

VLP Therapeutics

NCT06515990 RECRUITING

A Study of DM005 in Patients With Advanced Solid Tumors

Doma Biopharmaceutical（Suzhou）Co., Ltd.

NCT05902520 ACTIVE NOT RECRUITING

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

AgonOx, Inc.

NCT07274852 RECRUITING

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT05544929 ACTIVE NOT RECRUITING

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis Pharmaceuticals

NCT07232524 RECRUITING

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

NCT05327270 ACTIVE NOT RECRUITING

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

M.D. Anderson Cancer Center

NCT06022029 RECRUITING

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

OncoNano Medicine, Inc.

NCT02567422 ACTIVE NOT RECRUITING

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

NCT05859074 RECRUITING

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT06159621 ACTIVE NOT RECRUITING

CD40 Agonist and PD-1 Inhibitor in HNSCC

University of Pennsylvania

NCT03983954 ACTIVE NOT RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

NCT07081984 RECRUITING

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

Therorna

NCT07106827 RECRUITING

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

West China Hospital

NCT06332755 RECRUITING

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

LG Chem

NCT05238883 ACTIVE NOT RECRUITING

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

NCT05973487 ACTIVE NOT RECRUITING

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics, Inc.

NCT03589339 ACTIVE NOT RECRUITING

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Nanobiotix

NCT05783622 ACTIVE NOT RECRUITING

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Janux Therapeutics

NCT05945875 RECRUITING

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

NCT02446249 ACTIVE NOT RECRUITING

Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

MeiraGTx, LLC

NCT05653882 ACTIVE NOT RECRUITING

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Asher Biotherapeutics, Inc.

NCT05937269 ENROLLING BY INVITATION

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

The University of Texas Health Science Center, Houston

NCT05107674 RECRUITING

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

NCT06789172 RECRUITING

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Epkin

NCT07154108 NOT YET RECRUITING

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

Sichuan University

NCT05076760 RECRUITING

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Memgen, Inc.

NCT03170960 ACTIVE NOT RECRUITING

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

NCT04429542 RECRUITING

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Bicara Therapeutics

NCT05222932 ACTIVE NOT RECRUITING

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

TILT Biotherapeutics Ltd.

NCT07072325 NOT YET RECRUITING

Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

West China Hospital

NCT06761937 RECRUITING

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Erasmus Medical Center

NCT05540899 ACTIVE NOT RECRUITING

Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer

American College of Radiology

NCT03690986 RECRUITING

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Emory University

NCT02474368 ACTIVE NOT RECRUITING

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Dana-Farber Cancer Institute

NCT07036185 NOT YET RECRUITING

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

NCT05704985 ACTIVE NOT RECRUITING

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

NCT06540443 RECRUITING

Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas

MegaPro Biomedical Co. Ltd.

NCT05674526 ACTIVE NOT RECRUITING

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Wugen, Inc.

NCT03498378 ACTIVE NOT RECRUITING

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kathryn Gold

NCT06446713 RECRUITING

PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer

University Medical Center Groningen

NCT03212404 ACTIVE NOT RECRUITING

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

NCT06741982 RECRUITING

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

West China Hospital

NCT04576091 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

NCT05376553 ENROLLING BY INVITATION

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Krzysztof Misiukiewicz

NCT04593589 RECRUITING

Submandibular Gland Stem Cell Transplantation

University Medical Center Groningen

NCT05215574 ACTIVE NOT RECRUITING

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

NCT05200650 RECRUITING

A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor

IntraGel Therapeutics

NCT06614686 RECRUITING

U87 CAR-T in Patients With Advanced Head and Neck Tumors

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

NCT04999761 RECRUITING

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

NCT06259552 RECRUITING

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SparX Biotech(Jiangsu) Co., Ltd.

NCT05867303 ACTIVE NOT RECRUITING

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

RemeGen Co., Ltd.

NCT06109207 RECRUITING

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

West China Hospital

NCT06383507 NOT YET RECRUITING

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Zhejiang University

NCT05952947 RECRUITING

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

HRYZ Biotech Co.

NCT05582590 NOT YET RECRUITING

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

NexImmune Inc.

NCT05698238 NOT YET RECRUITING

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours

Mabpro, a.s.

NCT07589205 RECRUITING

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

NCT07613723 RECRUITING

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

Zelluna Immunotherapy AS

NCT07623369 NOT YET RECRUITING

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

Huahui Health

NCT04354246 COMPLETED

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

NCT06870487 TERMINATED

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Pfizer

NCT06091930 COMPLETED

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Boehringer Ingelheim

NCT03552718 COMPLETED

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NantBioScience, Inc.

NCT05983133 TERMINATED

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT04266730 SUSPENDED

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

UNC Lineberger Comprehensive Cancer Center

NCT06974734 TERMINATED

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Pfizer

NCT03881488 COMPLETED

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Compass Therapeutics

NCT03236935 COMPLETED

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

NCT02819752 TERMINATED

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Royal Marsden NHS Foundation Trust

NCT06110195 TERMINATED

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

University of Chicago

NCT04234113 TERMINATED

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

SOTIO Biotech AG

NCT01783587 COMPLETED

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Dana-Farber Cancer Institute

NCT06580938 TERMINATED

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Pfizer

NCT04042935 COMPLETED

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

University of Colorado, Denver

NCT07431645 COMPLETED

Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells

Institute of Oncology Ljubljana

NCT04290546 COMPLETED

CIML NK Cell in Head & Neck Cancer

Dana-Farber Cancer Institute

NCT07435311 COMPLETED

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

R-Pharm

NCT06546553 TERMINATED

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Pfizer

NCT05462873 TERMINATED

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT02989064 COMPLETED

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Adaptimmune

NCT04640480 COMPLETED

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

SN BioScience

NCT05827614 TERMINATED

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Boundless Bio, Inc.

NCT03978689 COMPLETED

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma

NCT03578406 COMPLETED

HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

Xinqiao Hospital of Chongqing

NCT03746431 TERMINATED

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Fusion Pharmaceuticals Inc.

NCT04045496 COMPLETED

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.

NCT06494189 COMPLETED

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

West China Hospital

NCT04840472 SUSPENDED

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

Stanford University

NCT06549816 COMPLETED

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Seagen, a wholly owned subsidiary of Pfizer

NCT03381183 COMPLETED

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT06052852 TERMINATED

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

NCT05229601 TERMINATED

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

NCT07216833 WITHDRAWN

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

NCT02586207 COMPLETED

Pembrolizumab in Combination With CRT for LA-SCCHN

Sanford Health

NCT04215978 COMPLETED

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

NCT04000529 TERMINATED

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis Pharmaceuticals

NCT06056310 TERMINATED

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

EMD Serono Research & Development Institute, Inc.

NCT06285097 TERMINATED

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Pfizer

NCT06338657 TERMINATED

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

University of Southern California

NCT03019003 COMPLETED

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Massachusetts General Hospital

NCT04344795 COMPLETED

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Tempest Therapeutics

NCT04879849 COMPLETED

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Takeda

NCT04105543 COMPLETED

CLR 131 Combined With Radiation for Head and Neck Cancer

University of Wisconsin, Madison

NCT04989387 TERMINATED

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Incyte Corporation

NCT05605522 TERMINATED

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

3B Pharmaceuticals GmbH

NCT02079324 COMPLETED

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

Genexine, Inc.

NCT02475213 COMPLETED

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

MacroGenics

NCT05585034 COMPLETED

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Xencor, Inc.

NCT02903914 COMPLETED

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Incyte Corporation

NCT04580485 COMPLETED

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT03336606 COMPLETED

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Providence Health & Services

NCT03289962 COMPLETED

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Genentech, Inc.

NCT03991741 TERMINATED

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Gregory Daniels

NCT03635164 COMPLETED

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

University of Colorado, Denver

NCT05432193 TERMINATED

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

NCT05788484 COMPLETED

A Study of CDX-585 in Patients With Advanced Malignancies

Celldex Therapeutics

NCT04152018 TERMINATED

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

NCT04121286 COMPLETED

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Allist Pharmaceuticals, Inc.

NCT02318771 COMPLETED

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03524326 COMPLETED

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT03894618 COMPLETED

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Shattuck Labs, Inc.

NCT04830592 COMPLETED

A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

Akamis Bio

NCT03195699 COMPLETED

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

NCT05576077 TERMINATED

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Turnstone Biologics, Corp.

NCT04465487 TERMINATED

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Regeneron Pharmaceuticals

NCT04502888 TERMINATED

Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

Shattuck Labs, Inc.

NCT04091867 COMPLETED

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

University of Colorado, Denver

NCT04588038 TERMINATED

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Hyunseok Kang, MD

NCT04254107 TERMINATED

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Seagen Inc.

NCT05053737 COMPLETED

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

University of Colorado, Denver

NCT03245489 COMPLETED

Anti-platelet + Pembro for H&N Tumors

Medical University of South Carolina

NCT03518554 COMPLETED

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.

NCT04217057 TERMINATED

Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer

Washington University School of Medicine

NCT04795713 TERMINATED

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Molecular Templates, Inc.

NCT06034860 TERMINATED

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

NCT04096638 COMPLETED

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

invoX Pharma Limited

NCT04870840 COMPLETED

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

M.D. Anderson Cancer Center

NCT03809624 TERMINATED

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Inhibrx Biosciences, Inc

NCT04628780 TERMINATED

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Pfizer

NCT03752398 COMPLETED

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Xencor, Inc.

NCT06357858 WITHDRAWN

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

NCT05578820 COMPLETED

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Gene Surgery LLC

NCT05538572 COMPLETED

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Prelude Therapeutics

NCT03666273 COMPLETED

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Bayer

NCT03629756 COMPLETED

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

NCT02308072 COMPLETED

Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer

University College, London

NCT05061537 TERMINATED

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Pfizer

NCT04659369 TERMINATED

Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

Taizhou Mabtech Pharmaceutical Co.,Ltd

NCT04881045 COMPLETED

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Pfizer

NCT03329950 COMPLETED

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

NCT03590054 COMPLETED

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Rahul Aggarwal

NCT04682431 TERMINATED

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Ikena Oncology

NCT05472506 WITHDRAWN

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Ikena Oncology

NCT05121948 TERMINATED

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

HiberCell, Inc.

NCT04902027 COMPLETED

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NCT04624113 TERMINATED

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Washington University School of Medicine

NCT02274155 COMPLETED

Anti-OX40 Antibody in Head and Neck Cancer Patients

Providence Health & Services

NCT04244552 TERMINATED

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Atreca, Inc.

NCT03219268 COMPLETED

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

MacroGenics

NCT03454451 COMPLETED

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

NCT02482168 COMPLETED

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

NCT03525392 TERMINATED

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Ipsen

NCT03229278 COMPLETED

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Rutgers, The State University of New Jersey

NCT04892875 WITHDRAWN

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Jennifer Choe

NCT01332682 COMPLETED

Resistance Training and Physical Functioning in Head and Neck Cancer Patients

University of Alabama at Birmingham

NCT02897375 COMPLETED

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Emory University

NCT03735628 COMPLETED

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Bayer

NCT05395052 TERMINATED

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

NCT04601402 COMPLETED

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Genome & Company

NCT04452214 COMPLETED

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Cantargia AB

NCT03829436 COMPLETED

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT04440943 COMPLETED

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Celldex Therapeutics

NCT04348916 TERMINATED

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Oncorus, Inc.

NCT02575404 COMPLETED

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Providence Health & Services

NCT03733210 COMPLETED

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Andrei Iagaru

NCT02376699 TERMINATED

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

NCT03841110 COMPLETED

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

NCT04043104 COMPLETED

A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

MeiraGTx UK II Ltd

NCT05220748 WITHDRAWN

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Rakuten Medical, Inc.

NCT03758781 COMPLETED

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

H. Lee Moffitt Cancer Center and Research Institute

NCT04413214 COMPLETED

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

Shanghai Jiao Tong University School of Medicine

NCT03849469 COMPLETED

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Xencor, Inc.

NCT04837677 COMPLETED

A Study of PRT1419 in Patients With Advanced Solid Tumors

Prelude Therapeutics

NCT03689192 COMPLETED

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Herlev Hospital

NCT03265080 TERMINATED

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Advaxis, Inc.

NCT01846091 COMPLETED

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Mayo Clinic

NCT02158234 COMPLETED

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

H. Lee Moffitt Cancer Center and Research Institute

NCT04430842 COMPLETED

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

NCT05393635 WITHDRAWN

ITIL-168 in Advanced Solid Tumors

Instil Bio

NCT04672980 TERMINATED

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Rubius Therapeutics

NCT04762225 TERMINATED

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Repertoire Immune Medicines

NCT03129061 COMPLETED

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

CellSight Technologies, Inc.

NCT03517488 COMPLETED

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor, Inc.

NCT02764593 COMPLETED

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

RTOG Foundation, Inc.

NCT02437916 TERMINATED

Safety Study of AMG 228 to Treat Solid Tumors

Amgen

NCT04060342 TERMINATED

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

NCT01668849 COMPLETED

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

University of Louisville

NCT02531906 COMPLETED

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

Roswell Park Cancer Institute

NCT04596033 TERMINATED

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

NCT01163487 COMPLETED

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Daniel T. Chang

NCT02646748 COMPLETED

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

NCT02526017 COMPLETED

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Five Prime Therapeutics, Inc.

NCT02178072 COMPLETED

Window Trial 5-aza in HNSCC, T-tare

Yale University

NCT01391143 COMPLETED

Safety Study of MGA271 in Refractory Cancer

MacroGenics

NCT02628535 TERMINATED

Safety Study of MGD009 in B7-H3-expressing Tumors

MacroGenics

NCT00967577 COMPLETED

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Weill Medical College of Cornell University

NCT04316689 COMPLETED

First-in-human Study of S-588210 (S-488210+S-488211)

Shionogi

NCT03319459 COMPLETED

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Fate Therapeutics

NCT03652077 COMPLETED

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Incyte Corporation

NCT02636036 COMPLETED

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Akamis Bio

NCT04252248 TERMINATED

Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage

University Hospital Heidelberg

NCT01353625 COMPLETED

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Celgene

NCT02415881 COMPLETED

Panitumumab IRDye800 Optical Imaging Study

Eben Rosenthal

NCT04099277 TERMINATED

A Study of LY3435151 in Participants With Solid Tumors

Eli Lilly and Company

NCT03022409 COMPLETED

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

AstraZeneca

NCT02544880 COMPLETED

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Donald T. Weed, MD, FACS

NCT02537223 COMPLETED

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

University Health Network, Toronto

NCT02201355 TERMINATED

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

University of Texas Southwestern Medical Center

NCT03818542 TERMINATED

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

AbbVie

NCT01598077 COMPLETED

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Novartis Pharmaceuticals

NCT03246854 TERMINATED

A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

National Health Research Institutes, Taiwan

NCT03538028 COMPLETED

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Incyte Biosciences International Sàrl

NCT03957096 TERMINATED

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Seagen Inc.

NCT02325401 COMPLETED

Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Cincinnati

NCT01057277 TERMINATED

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

howard safran

NCT02576665 TERMINATED

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

NCT02048917 COMPLETED

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

University of Kentucky

NCT02686008 WITHDRAWN

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Yale University

NCT02429089 TERMINATED

Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT03811652 COMPLETED

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

MedImmune LLC

NCT01445405 COMPLETED

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

National Cancer Institute (NCI)

NCT00924092 COMPLETED

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

National Cancer Institute (NCI)

NCT02110992 TERMINATED

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

University of Cincinnati

NCT02124850 TERMINATED

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Celgene

NCT01758731 COMPLETED

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

University of Colorado, Denver

NCT02473731 COMPLETED

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Celldex Therapeutics

NCT00832559 TERMINATED

A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)

Viralytics

NCT01987375 TERMINATED

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Eben Rosenthal

NCT01017185 COMPLETED

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Takara Bio Inc.

NCT02069158 COMPLETED

Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor

Cristiana Sessa

NCT00978081 COMPLETED

Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors

Abramson Cancer Center at Penn Medicine

NCT02277197 COMPLETED

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

James J Lee

NCT01716416 COMPLETED

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

NCT02565758 COMPLETED

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

AbbVie

NCT02508246 COMPLETED

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

University of Washington

NCT00896350 TERMINATED

MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer

University of Texas Southwestern Medical Center

NCT01871311 TERMINATED

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Georgetown University

NCT02205398 TERMINATED

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis Pharmaceuticals

NCT00882583 TERMINATED

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01493154 TERMINATED

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02960594 COMPLETED

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Inovio Pharmaceuticals

NCT00675233 COMPLETED

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Roswell Park Cancer Institute

NCT01986426 COMPLETED

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

NCT02350712 COMPLETED

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Daiichi Sankyo

NCT01540682 COMPLETED

MLN8237 in Head and Neck Cancer

Abramson Cancer Center at Penn Medicine

NCT02543645 TERMINATED

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Celldex Therapeutics

NCT00901537 TERMINATED

Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Loma Linda University

NCT02365662 TERMINATED

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

NCT01520389 COMPLETED

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

NCT02921984 COMPLETED

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT01804205 COMPLETED

Magnesium Sulphate and Rocuronium in Patients Over 60

Pedro Rotava

NCT01384799 COMPLETED

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Curis, Inc.

NCT01012362 TERMINATED

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638 COMPLETED

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT02216617 COMPLETED

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy

Groupe Oncologie Radiotherapie Tete et Cou

NCT01721525 COMPLETED

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Memorial Sloan Kettering Cancer Center

NCT02262741 COMPLETED

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

MedImmune LLC

NCT01727076 COMPLETED

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

National Cancer Institute (NCI)

NCT02211027 WITHDRAWN

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

Robert Ferris

NCT02538627 TERMINATED

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Merrimack Pharmaceuticals

NCT01911598 COMPLETED

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Genentech, Inc.

NCT02251639 WITHDRAWN

Diagnostic Aids for Detection and Diagnosis of Oral Cancer

M.D. Anderson Cancer Center

NCT00937417 WITHDRAWN

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

SWOG Cancer Research Network

NCT02567396 WITHDRAWN

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT02110082 COMPLETED

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Bristol-Myers Squibb

NCT00903461 TERMINATED

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

NCT01046266 COMPLETED

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Hoffmann-La Roche

NCT01451632 COMPLETED

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

NCT01975688 TERMINATED

A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis

GW Pharmaceuticals Ltd

NCT00377247 TERMINATED

Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

University of Pittsburgh

NCT00731380 COMPLETED

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

University Health Network, Toronto

NCT01737008 COMPLETED

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

University Health Network, Toronto

NCT00670397 TERMINATED

Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

Roswell Park Cancer Institute

NCT01171924 COMPLETED

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Curis, Inc.

NCT01036412 COMPLETED

Chlorhexidine Gel Therapy for Cariogenic Oral Microflora

M.D. Anderson Cancer Center

NCT00779389 COMPLETED

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

University of Pittsburgh

NCT00625456 COMPLETED

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Jennerex Biotherapeutics

NCT01310179 COMPLETED

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

PNP Therapeutics, Inc.

NCT01379339 COMPLETED

Cabazitaxel - PF Induction Chemotherapy

Krzysztof Misiukiewicz

NCT00738751 COMPLETED

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

H. Lee Moffitt Cancer Center and Research Institute

NCT00968656 COMPLETED

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

Washington University School of Medicine

NCT01360827 TERMINATED

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Merck KGaA, Darmstadt, Germany

NCT00918762 COMPLETED

Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx

Barbara Ann Karmanos Cancer Institute

NCT01255800 COMPLETED

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

University of Colorado, Denver

NCT01184482 COMPLETED

Lapatinib and Cetuximab in Patients With Solid Tumors

Georgetown University

NCT00858663 COMPLETED

Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT01058408 TERMINATED

RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Dana-Farber Cancer Institute

NCT00937300 WITHDRAWN

T-cell Based Immunotherapy for Head and Neck Cancer

Inge Marie Svane

NCT07405086 RECRUITING

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

NCT06162377 RECRUITING

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

M.D. Anderson Cancer Center

NCT07189897 RECRUITING

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Kiranya Arnold

NCT06879691 ACTIVE NOT RECRUITING

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Biotech Pharmaceutical Co., Ltd.

NCT06807034 ACTIVE NOT RECRUITING

Impact of the Oral Microbiota on Relapse in HNSCC Patients

Institut Sainte Catherine

NCT06734598 RECRUITING

Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy

National Taiwan University Hospital

NCT06521697 NOT YET RECRUITING

Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery

National Taiwan University Hospital

NCT07635420 NOT YET RECRUITING

Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)

Region Skane

NCT07633613 NOT YET RECRUITING

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Centre Antoine Lacassagne

NCT05859711 COMPLETED

Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients

Ain Shams University

NCT04489888 COMPLETED

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Merck Sharp & Dohme LLC

NCT06879366 COMPLETED

Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial

October 6 University

NCT04977271 WITHDRAWN

Mood Disorders in Head and Neck Cancer Patients

University of Alabama at Birmingham

NCT04246697 COMPLETED

Multimodal Pain Study in Free Flap Patients

University of Kansas Medical Center

NCT02484677 COMPLETED

Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy

Assistance Publique Hopitaux De Marseille

NCT05046028 COMPLETED

Individualization of Nutritive Sensory Support Of Radiation Therapy

National Medical Research Radiological Centre of the Ministry of Health of Russia

NCT05055726 COMPLETED

Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

Aziende Chimiche Riunite Angelini Francesco S.p.A

NCT04155008 TERMINATED

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Montefiore Medical Center

NCT01553032 COMPLETED

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

University of Heidelberg Medical Center

NCT03607227 COMPLETED

Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery

Region Skane

NCT03714867 WITHDRAWN

Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery

Augusta University

NCT01344356 COMPLETED

Stereotactic Body Radiotherapy for Head and Neck Tumors

Mercy Research

NCT03998696 COMPLETED

An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

NCT02926573 COMPLETED

Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients

Washington University School of Medicine

NCT02049112 COMPLETED

A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study

Unither Pharmaceuticals, France

NCT01418118 COMPLETED

Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery

Oxford University Hospitals NHS Trust

Full Head and Neck Cancer Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Head and Neck Cancer landscape

How many companies are developing Head and Neck Cancer treatments?: 11 companies have active or registered Head and Neck Cancer programs in TheraRadar's competitive landscape (91 classified trials). The most active are Sichuan Baili, GSK, and Johnson & Johnson.
What mechanisms of action are being developed for Head and Neck Cancer?: 14 distinct mechanisms of action appear across the Head and Neck Cancer pipeline, including EGFR / HER3 bispecific ADC, EGFR × HER3 bispecific, PD-1 (dostarlimab), EGFR × HER3 bispecific ADC, and EGFR / MET bispecific.
What is the most crowded mechanism in Head and Neck Cancer?: EGFR / HER3 bispecific ADC is the most contested mechanism in Head and Neck Cancer, with 6 programs mapped to it.
Are there upcoming Head and Neck Cancer clinical readouts or FDA decisions?: Near-term Head and Neck Cancer catalysts include SYS6010 injection (data readout, Jun '26); Pembrolizumab (FDA decision, Aug '26); BL-B01D1 (data readout, Nov '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Head and Neck Cancer landscape data come from?: Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Head and Neck Cancer heatmap free to use?: Yes — viewing and searching the Head and Neck Cancer heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.

How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

Healthy-volunteer studies are set aside as non-disease trials.
Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
🌱 First-in-indication — the only program competing on that mechanism within this disease.
🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
Sponsor names are as-filed and may lag current ownership.
Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only